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vExecutive Summary
Biotechnology has to be understood as a system or network. Innovative
activities, as well as production and commercialisation, rest on and involve,
either directly or indirectly, a large variety of actors: different types of firms,
other research organisations like universities and non-industrial research
centers, financial institutions, regulatory authorities, governments, health care
systems, consumers, etc.
The competitiveness of innovation and production systems in biotechnology
cannot be assessed by looking only at the individual firms, but also at the
broader set of institutions, infrastructures, and policies that influence the
actions of companies, and – even more important – at the dynamic interactions
between these levels of analysis.
The distinctive features of this industry are the strong relationship between
innovation and competitiveness, the collaborative basis of research, and the
importance of small firms. Biotechnology highlights the importance of firms’
“capabilities” – the ability to mobilise and exploit new knowledge and to reach
out and exploit collaboration among agents and across stages of product
development, scientific disciplines and industry frontiers. The sector is
characterised by a new breed of agents, small specialised firms – dedicated
biotechnology firms (DBFs) – that have entered the industry with the explicit
aim of exploiting the new technologies of life sciences for different industrial
purposes. These firms are having a remarkable and radical impact on
pharmaceuticals and agriculture.
Patent and collaborative R&D projects data indicate that the US has
accumulated and maintains a dominant advantage in innovative activities in
biotechnology compared to Europe. Europe in fact lags significantly behind the
US in all facets of the commercial development of biotechnology. There is now
agreement that this leadership originates essentially in the strength of its DBFs
and, more generally, in the development of a deep market for technology.
Nevertheless, some of the smaller European countries (Ireland, the Netherlands
and the Nordic countries) appear to specialise successfully in biotechnology.
Also an intense dynamism has been observed recently in firms’ entry – from
vi
1996 to 2000 the population of independent European DBFs almost doubled to
close to 2,000 – as well as in clustering of research and production in Europe.
In 1999 and 2000, after a 4-year period of intense entry, in which the overall
number of EU biotechnology firms almost doubled, the rates of company
formation have decreased. This slowdown (not corroborated by Ernst &
Young’s data) seems to be similar, in nature, to the one observed in the USA at
the beginning of the Nineties.
According to the BID data set at the University of Siena, the distribution of
biotechnology DBFs in Europe is led by Germany and the UK (with over 500
DBFs) followed by France and Sweden (with at least 200 DBFs). The BID data
set indicates that activity is also prominent across the rest of the European
nations, ranging from around 30 DBFs in Spain to close to 100 in Switzerland.
It may be argued that Europe’s lag behind the US in biotechnology is partly a
reflection of its late entry. Innovative activities are generally characterised by
increasing returns and being first provides long-lasting leadership. But this may
not be the only factor. A fundamental precondition for a successful
development of biotechnology is the availability of leading-edge scientific
capabilities – without a strong and diversified scientific research base, no
technological take–off is possible. Moreover, success in this industry depends
on a delicate blend of competencies and incentives and requires
decentralisation of efforts, a diversity of approaches, as well as co-ordination
of several differentiated agents, capabilities and functions. In particular, new
European DBFs are generally smaller than their US counterparts, less active in
global networks and collaborative relationships and fewer are present in
markets for these technologies. Access to an international scientific community
requires direct and active participation in networks of scientists. One finding of
the Report is the unattractiveness of the European environment to US research:
comparatively little US research is done in Europe.
The European research system in the life sciences and in biotechnology is still
too fragmented. To a considerable extent, this fragmentation may be due to
regulatory, entrepreneurial, fiscal and financial factors. However, in addition to
these factors, the supply of cutting-edge scientific research may be inadequate.
If so, this problem could be addressed not only through higher levels of
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research funding but also through higher degrees of pluralism in funding
sources, lower dependence on closed national systems, and higher integration
of research with teaching, clinical research and medical practice. One of the
most effective means of achieving this would be through the establishment of a
European Research Area. European DBFs are still far too small and too
specialised in specific niches and they manifest an insufficient ability to access
and make efficient use of networks of collaborative research. Although there
has been some success, notably in the promotion of biotechnology start-ups,
the growth of DBFs in Europe appears to be hindered.
DBFs exist in a relationship of strong complementarity with large corporations.
The latter are not only the fundamental source of demand for the products and
services of DBFs but, equally importantly, they also provide the integrative
capabilities that transform fragments of knowledge into products and constitute
precious reservoirs of technological and managerial competencies. The
importance of the relationships between the creation and development of DBFs
and the research/absorptive capabilities of the large companies make it clear
that policies for biotechnology should be much more strongly linked to policies
aiming at raising the competitiveness of “downstream” industries, such as
pharmaceuticals and agriculture.
Policies for biotechnology have been in place for several years in Europe, and
some important results have been achieved.
The promotion of the creation of DBFs has been central to European
biotechnology policies for more than a decade. Still, with the policy emphasis
on industry–university relations, on creating the “entrepreneurial university”,
on venture capital and on intellectual property rights, the problem of an
inadequate supply of cutting–edge scientific research may not have been
sufficiently addressed. Increased funding is only a part of the solution.
Higher degrees of pluralism in funding sources, lower dependence on closed
national systems, higher integration of research with teaching, clinical research,
and medical practice, together with a higher reliance on interdisciplinary
research teams in the life sciences, should become priorities of a European
research policy biotechnology.
I. Introduction
This Report analyses the current status of innovation and production systems in
European biotechnology, and, in particular, the innovative capacity and related
factors that are some of the major determinants of the competitiveness of European
biotechnology firms.
As such, biotechnology cannot be considered as an industrial sector, but rather a set
of technologies. Its applications span a number of industrial and service sectors, as
well  as agriculture. This direct link with science makes innovative capacity an
important determinant of competitiveness.
While large biotechnology firms are undoubtedly important, the emphasis of the
chapter is on the role of the small and medium, research-intensive companies, which
have emerged from the new opportunities opened up by the life sciences. In the
present chapter they are referred to as dedicated biotechnology firms (DBFs).
DBFs are primarily university spin-offs that mobilize scientific and technological
knowledge and transform it into potentially commercially useful techniques and
products. These firms are usually formed through collaboration between scientists
and professional managers, backed by venture capital. Their specific skills reside in
the knowledge of new techniques and in research capabilities.
Inevitably, comparisons with the US biotechnology industry are made throughout. In
the United States, biotechnology was the motive force behind the first large-scale
entry into the pharmaceutical industry since the early post World War II period.
Entry rates soared in 1980 and remained at a very high level thereafter, with waves
linked to both the stock market performance and to the appearance of successive new
technologies. One notable difference between Europe and the US in the 1980s and at
the beginning of the Nineties has been that, while in the US a new research–intensive
industry in the life sciences has continued to develop, there has been no equivalent
specialisation in entrepreneurial biotechnology in Europe (see also Gambardella,
Orsenigo, Pammolli, 2001). Partly reflecting this difficulty to develop an industry of
DBFs, the perception has emerged that the US has a competitive advantage over
Europe in biotechnology.
2The US have pioneered the emergence of an effective division of labour between
new, small companies, large corporations and other research institutions, which have
different comparative advantages in the “exploration” and “exploitation” of new
innovation opportunities (March, 1991).  Europe has been less effective in
facilitating the growth of research-intensive DBFs.
While large multinationals, such as biopharmaceuticals and agro-food, may not need
local technology suppliers, the presence of a local industry of research–based firms
and technology suppliers is critical. On the one side, despite tendencies towards a
wider internationalisation of research, high technological performances tend to be
linked to home-based research capabilities. On the other side, the “biotechnology”
industry is, by itself, a powerful source of growth and social progress. The US
biotechnology industry has generated, over the past two decades, a large number of
new jobs and at least a dozen new world-class companies (e.g. Amgen, Chiron,
Genzyme, and others), along with several new others in the new general purpose
technologies (e.g. Incyte, Human Genome Sciences, Millennium, Celera, and others).
It has also produced a stream of revenues, most frequently in the form of royalties
from licenses or R&D contracts and collaborations.
Given the impact of biotechnology on social and economic progress, as well as its
effects on downstream industries, both national European governments and the
European Commission have developed a strong anxiety about European
competitiveness in this field and have promoted the birth of a new industry of
dedicated biotechnology firms.
Particularly in recent  years, the perception has started to diffuse of a new dynamism
in European biotechnology.
However, the features and contribution of the new European DBFs have not been the
object of systematic comparative investigations, and much of the empirical material
on innovation and production systems in biotechnology is based on the American
experience.
Moreover, many statistical and methodological problems affect the quality and
reliability of the currently available data on European biotechnology. For example,
3the lack of standardised survey procedures prevents the existence of comparable
indicators on many relevant issues1. In some cases, the coverage of biotechnology is
incomplete, while other data sources drastically overstate the impact and the
expected rates of growth of biotechnology.
In synthesis, any comparison among nations and regions, in terms of biotechnology
policies, scientific and technological capabilities, and industrial competitiveness, is
severely limited, at present, by currently available data sources and statistics.
Against this background, the first goal of the Report is to expand  empirical
knowledge on the current state and performance of the new European biotechnology
industry. Then, the Report gives an assessment of the institutional, legal, cultural and
industrial variables that affect industrial growth and competitiveness in
biotechnology.
The Report integrates available statistics and sources of information with an original
data set specifically aimed at giving an account of the structure of industrial
biotechnology in Europe. BID (the Biotechnology Industry Database), developed by
the Epris Research Unit at the University of Siena, provides information on location,
number of employees, technological and market specialisation, R&D and
collaborative activities, of biotechnology firms across Europe, with particular
reference to the small Dedicated Biotechnology Firms (DBFs).
Other data for this Report come from OECD, Eurostat, government statistics, from
statistics collected by publicly funded organisations such as the US National Science
Foundation in the US and NUTEK in Sweden, the most important patent offices, and
from commercially available databases such as Windhover, Recombinant Capital,
and Bioscan. Reports and data from commercial sources like Ernst&Young, Decision
Resources, SRI, McKinsey, the European Venture Capital Association, have also
been used.
The Report is organised as follows.
                                                
1 “Many basic indicators are available that are similar in purpose, such as biotechnology employment or the
number of ‘core’ biotechnology firms, but the definition of employment or a ‘core’ firm varies from country to
country. In some countries, we do not even have basic information on the definitions or descriptions of survey
methodologies” (van Beuzekom, 2001, p. 4).
4Section II presents the main general indicators of European innovative activities in
biotechnology. Section III provides a detailed analysis of R&D activities and
research collaborations of European biotechnology companies, in the context of the
international division of innovative labour within the field. Section IV analyses the
structure of the new European biotechnology industry and the new DBFs that entered
the industry during the 1990s, while Section V analyses the essential features of
biotechnology clusters in Europe. Section VI reviews briefly the institutional, legal,
and cultural factors that have an impact on the evolution and performances of the
biotechnology industry. The final section summarises the main findings of the
Report.
5II.  Innovative Activities in the European Biotechnology Industry
II.1. Introduction
This section provides an overview of the innovative performance of industrial
biotechnology in Europe. It looks first at the general structure and trend in innovative
activities, as measured by patent data and patent citations. Second, it examines in
more detail the localisation of inventive activities in biotechnology across macro-
regions and  countries, always relying on patent data.
The use of patents as an indicator of innovative output is largely justified by the
peculiarity of the technology and the widespread patenting practices at all levels of
the industry. While in other industries patents are a highly imperfect indicator, in
biotechnology they closely reflect innovation output (see also the discussion in
Gambardella, Orsenigo, Pammolli, 2001).
II.2. General Trends
The available empirical evidence shows that the US are and continue to be the most
important locus of innovation in biotechnology (see Figure 2.1; Figure 2.2), followed
by Japan, Germany, UK, and France.
Figure 2.1 gives an account of the dominance of the US in biotechnology inventions.
From 1990 to 2000, the United States increased by 9 percentage points its share of all
biotechnology patents granted by the USPTO2. The share of Japan declined by 11 %.
A modest increase occurred in the case of Denmark (+ 1.1%), while Germany lost a
little ground (- 1.2%). The shares of all other European countries have remained
relatively stable over the last decade.
                                                
2 Biotechnology patents are covered by class 435 of the USPTO classification system (“molecular biology and
microbiology”). For a complete definition of class 435 see
http://www.uspto.gov/web/offices/ac/ido/oeip/taf/moc/435.htm.
6Between 1990 and 1997, national shares of biotechnology EPO patent applications3
were relatively stable (see Figure 2.2), with the exception of Japan, which saw a
decline of 6%. The UK shows the strongest performance (+ 2.1%).  The shares of the
other European countries have remained relatively stable over time.
Figure 2.1: Biotechnology patents granted by the USPTO, 1990 and
2000
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Source: OECD, calculations based on data from USPTO
Patent citation data provide a better measure of the technological and economic
potential value of innovative activities than patent counts. Citations are a measure of
the importance or impact of inventions and a proxy for knowledge flows among
patenting institutions. Widely-cited patents tend to be “seminal” patents, i.e. key
inventions which further patents must refer to. Moreover, high citation rates have
been shown to correlate with the economic value of patents. Thus, a high number of
                                                
3 European biotechnology patents are covered by 5 IPC codes: C12M: Apparatus for enzymology or
microbiology; C12N: Micro-Organisms or Enzymes; compositions thereof; C12P: Fermentation or enzyme-using
processes to synthesise a desired chemical compound; C12Q: Measuring or testing processes involving enzymes
or micro-organisms; C12S: Processes using enzymes or micro-organisms to liberate, separate, or purify a pre-
existing compound or composition. For complete definitions of these IPC codes, see
http://classifications.wipo.int/fulltext/new_ipc/index.htm.
7citations received by a given firm or country can be interpreted as a measure of the
quality and relevance of its innovative activities.
Data not reported here for reasons of space (see Lacetera and Orsenigo, 2001), show
that the share of citations referring to US patents is substantially higher (around 55%)
than the share of simple counts, suggesting that on average US patents are relatively
more important. Moreover, among European countries, only UK patents show a
higher share  for citations than for patent counts.
Figure 2.2: Biotechnology patent applications to the EPO for priority
years 1990 and 1997
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Source: OECD, calculations based on data from USPTO and EPO
On the basis of a subset of “highly cited” patents (i.e. patents receiving at least 10
citations in the period not counting self-citations) in the period 1978 – 1995 (with
citations up to 1997), the US lead increases further to 65.4%.
DBFs hold a disproportionate share of these highly cited patents (48%), and US
DBFs account for more than 80% of DBFs' highly cited patents. In Europe (including
Switzerland), around 65% of the highly cited patents belong to large incumbent firms
and around 20% to DBFs (almost all of them British). Considering the top twenty
8institutions in terms of patent citations (i.e. institutions having the higher number of
patent citations), 11 are American (4 DBFs, 3 incumbents, 4 universities and other
research organisations), 2 are, respectively, German, British and Japanese, while
Switzerland, France and Denmark appear with one institution. Almost all of these
European institutions are large corporations, with the only exceptions of one British
DBF and one French public research organisation. At a more aggregate level,
however, it is important to notice that Sweden turned out  to have the highest share of
highly cited patents in the life sciences filed in 1994-1998 (see US Council on
Competitiveness, 2001).
Patent data show also that the USA are relatively more specialised in the
pharmaceutical segment of biotechnology. Their share of highly cited agro-food
patents is 13.5% as compared to a total of 17%. Only two European countries have
highly cited agro-food patents, namely Germany (35% ) and the UK (33%) of their
total highly cited patents.
The growth and impact of biotechnology is affected, to a certain extent, by the size
and the growth of ‘downstream’ industries, which demand biotechnology products
and technologies (see also Gambardella, Orsenigo, Pammolli, 2001).
Table 2.1 shows, over a period of twenty years, the shares on GDP of the most
important industries related to biotechnology: food, chemicals, and pharmaceuticals,
for the US, Japan, and four major European countries: Germany, France, the UK, and
Sweden. The data in Table 2.1 shows a continuous growth of the share of
pharmaceuticals, with double-digit growth, while the shares of the food industry on
GDP decrease significantly.
The countries that recorded the highest growth in the GNP share of pharmaceuticals
are the US and the UK, while Germany and Japan experienced a much slower
growth. As for chemicals, UK, Germany and France have the highest share in GNP.
9Table 2.1: International Patterns of Specialization in Related Industries: Share of
GNP in Food, Pharmaceutical and Chemical1 Industries, 1978-97, Main Countries
Average share of GDP
1978-1985 1986-1993 1994-1997
Food 19,11 % 17,97 % 17,00 %
Chemicals1 19,03 % 18,00 % 19,66 %United Kingdom
Pharmaceuticals 1,50 % 2,14 % 2,78 %
Food 14,46 % 12,82 % 11,77 %
Chemicals1 20,31 % 17,71 % 18,61 %Germany
Pharmaceuticals 1,11 % 1,32 % 1,43 %
Food 17,79 % 17,01 % 16,68 %
Chemicals1 19,47 % 16,40 % 18,11 %France
Pharmaceuticals 1,65 % 2,24 % 2,65 %
Food 4,06 % 2,78 % 2,81 %
Chemicals1 12,87 % 10,69 % 10,25 %Sweden
Pharmaceuticals 0,85 % 1,67 % 2,72 %
Food 14,27 % 14,36 % 13,35 %
Chemicals1 19,42 % 16,69 % 16,59 %USA
Pharmaceuticals 1,17 % 1,83 % 2,21 %
Food 11,07 % 10,90 % 11,11 %
Chemicals1 14,47 % 9,52 % 11,28 %Japan
Pharmaceuticals 1,26 % 1,42 % 1,56 %
Remark: 1 Except Drugs
Source: OECD, STAN Database (2000)
II.3. R&D Activities and Research Collaborations: Inter-Country and Inter-
Regional Comparisons4
Patent data provide important information about the geographical distribution of
biotechnology research across macro-regions (Europe and the US) and across
countries. The extent to which companies locate biotechnology research outside of
their home country (internationalisation of research) is also important. To put the
analysis in perspective, biotechnology is compared with four other branches of the
chemical industry (materials, organic chemistry, pharmaceuticals, and polymers).
The analysis is based on the following data:
                                                
4 This section is based on Mariani, 2001.
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The European Patent Office. A data base of 97,785 chemical patent applications
between 1987-1996, covering five main technological sectors: biotechnology,
materials, organic chemistry, pharmaceuticals and polymers5.
The European R&D database (by Reed Elsevier Publisher). This data base provides
information on 7,264 laboratories located in Europe that perform research in
chemicals, pharmaceuticals, and biotechnology. The laboratories are classified as
private if they are firms’ labs, or public if they belong to government research
institutions, universities, or hospitals.
A random sample of 10,000 chemical patents drawn from the original sample of
97,785 patents. The data base includes: the number, name and addresses of the
assignees; the number, name and addresses of the inventors; the primary IPC class,
and the number and type of supplementary IPC classes; the date of the patent
application. Based on Who Owns Whom all company assignees have been classified
under the name of the ultimate parent company/institution.
Location of research activities
It is assumed that the location of the inventors of the (97,785) patents and the
location of the (7,264) chemical R&D laboratories coincide with the location of the
inventive activity.
The data suggest that the US are comparatively more specialised in biotechnology
innovations, and that some of the smaller European countries show greater
specialisation in biotechnology compared to larger European countries.
Figure 2.3 shows the sectoral break down of patents by subsectors. In 1987-1996
biotechnology patents were 17% of the total chemical patents. This ratio has
increased over time from 16% in 1987-1991 to 19% in 1992-1996. Clearly, these are
EPO patents that include patents developed in Europe and in other countries, like the
US and Japan. Figure 2.4 shows the share of patents attributed to each country.
                                                
5 The classification was developed by a research unit coordinated by R. Pammolli, a pharmacologist, who
assigned the 3-digit IPC (International Patent Classification) classes in chemicals (and in chemical related
technologies) to one of the five sectors above. We attributed each patent to one of these five sectors according to
whether its main IPC class belonged to that sector. Since our expert did not feel comfortable with assigning all 3-
11
Figure 2.3: Share of Patents by Chemical Class (1987-1996)
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Source: Elaboration on European Patent Office (1998)
Figure 2.4: Share of 1987-1996 EPO Patents in Chemicals by
Country of Invention
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digit IPC classes in chemicals and especially in chemical related technologies to one of the five sectors, the
concordance could be safely done only for 97, 785 patents rather than the whole set of 201,531 patents.
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The biotechnology patents invented in Europe represent 14.4% of the total number of
chemical patents invented in Europe, compared to 22.5% of the EPO biotechnology
patents invented in the US over the total number of chemical EPO patents invented
in the US. This suggests that the US chemical companies are relatively more focused
than European ones on biotechnology. To examine this issue further, the Revealed
Technological Advantage Index (RTA) was computed for different countries. RTA is
a country's share of all patenting in a given technology/sector relative to the share of
patents in that technology/sector over all technologies/sectors, and it gives an
account of the specialisation of a country or region in a technological field (Soete,
1989; Archibugi and Pianta, 1992; Caniels, 1999). The index is defined as
 J ijiijiJ ijij PPPP )/(/)/( , where P denotes the number of patents in
country/region i and sector j. Table 2.2 shows the Standardised Revealed
Technological Advantage Index (SRTA) = (RTA-1)/(RTA+1), for Europe, the USA
and Japan. The standardised index varies between –1 (non-specialisation) and 1
(specialisation). The evidence in Table 2.2 suggests that the US has a stronger
specialisation in biotechnology than Europe (and Japan). The SRTA index for the US
in biotechnology is 0.13 compared to –0.09 for Europe, and –0.12 for Japan.
Table 2.2: Standardised Revealed Technological Advantages of Europe, USA, and
Japan in biotechnology, materials, organic chemistry, pharmaceuticals and polymers
(97,785 patents in 1987-1996).
(RTA-1) / (RTA+1)
Country Biotech. Materials Organic
chemistry
Pharma Polymers
EU total (*) -0,09 0,01 0,06 0,02 -0,05
US 0,13 -0,06 -0,08 0,01 -0,01
JP -0,12 0,08 0,01 -0,11 0,15
OTHERS 0,22 0,02 -0,08 0,11 -0,39
(*) This is EU-15 plus Switzerland (CH) and Norway (NO)
Source: Elaboration on European Patent Office (1998)
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Table 2.3: Standardised Revealed Technological Advantages of European countries
in biotechnology, materials, organic chemistry, pharmaceuticals and polymers
(97,785 patents in 1987-1996) (*)
(RTA-1)/(RTA+1)
Country Biotech. Materials Organicchemistry Pharma Polymers
D -0,31 0,05 0,12 -0,08 0,07
F -0,03 0,08 0,01 0,12 -0,22
UK 0,01 -0,14 0,04 0,16 -0,37
I -0,24 -0,07 0,00 0,09 0,05
CH -0,17 -0,40 0,25 -0,06 -0,27
NL 0,15 0,16 -0,14 -0,18 0,15
IRL 0,23 0,02 -0,30 0,19 -0,24
B 0,02 0,14 -0,23 0,06 0,12
S 0,25 -0,07 -0,28 0,26 -0,55
DK 0,41 -0,29 -0,12 0,06 -0,80
E -0,02 -0,21 0,19 0,05 -0,54
A 0,34 0,19 -0,19 -0,10 -0,16
FIN 0,12 -0,08 -0,29 0,01 0,18
N 0,45 0,42 -0,30 -0,14 -0,54
GR 0,39 0,02 -0,31 0,03 -0,28
L -1,00 0,31 -0,24 -0,14 0,42
Remark: (*) Portugal is excluded because it had too few patents
Source: Elaboration on European Patent Office (1998)
Table 2.3 reports the standardised RTA by individual European country. It shows
that it is the larger European countries that show no specialisation in biotechnology
compared to the other branches of the chemical industry. The standardised
biotechnology RTA for Germany (–0.31), Italy (–0.24), France (–0.03) and the UK
(0.01) are negative or very close to zero. By contrast, the standardised biotechnology
RTA for the smaller European countries – Denmark (0.41), Ireland (0.23), the
Netherlands (0.15), Sweden (0.25), Finland (0.12) and Norway (0.45) – is positive
and has a large value. Germany and the UK have dominated the traditional chemicals
industry for many years while Italy and France have also been important worldwide.
The RTA results indicate that whereas the latter countries continue to focus their
activities in traditional chemicals, smaller European nations do not. Thus, the
traditional dominance of the larger European nations in chemicals seems to lead
them to do a higher proportion of their research in traditional areas of biotechnology.
The results shown by Tables 2.2 and 2.3 are confirmed by simple ratios of total
biotechnology patents over the total number of patents by country of invention. Table
2.4 shows that 45.4% of the total biotechnology patents in the sample were invented
14
in the US and 36.5% biotechnology patents invented in Europe. However, in all
chemical sectors the US share is 34.5% while Europe’s share is 44.8%.
As for individual countries, the share of biotechnology patents invented in Germany
over the total number of biotechnology patents in the sample is 9.9%. The shares of
organic chemistry and polymer patents invented in Germany over the total number of
patents in each of these two sectors are respectively 23.7% and 21.8%. The
differences are less striking for the other large European countries. In particular, the
share of pharmaceutical patents invented in France over the total number of
pharmaceutical patents is 8.5%, and the share of French patents in materials is 7.8%.
The same percentages for biotechnology, organic chemistry, and polymers are
respectively 6,3%, 6,8%, and 4,3%. The UK is specialised in organic chemistry and
pharmaceuticals: 7.4% and 9.3% of the total patents in each of the two sectors. The
percentages for the other three technological sectors are smaller. Consistently with
the results shown in Table 2.3, there is a higher percentage of biotechnology patents
invented in the smaller European countries, notably the Netherlands, Sweden,
Denmark, Ireland, and Austria, than the share of patents in the other classes that were
invented in these countries.
The data on the R&D laboratories also shed light on the comparative specialisation
of European countries in biotechnology. Of the 7,264 chemical R&D labs in the
sample, 32% perform biotechnology research6. Smaller countries (Denmark, Finland,
Ireland, and the Netherlands) are more focused on biotechnology than the larger
countries (Italy, Germany, and France), thus confirming the results seen earlier7.
Finally, about 72% of the biotechnology laboratories in the sample are public (i.e.
government research institutions, universities, and hospitals). The evidence across
countries is mixed. In Finland and in Ireland, 82.9% and 80.6% of the biotechnology
labs are public. This percentage drops to 67.7% in Denmark, and to 56.8% in the
                                                
6 Each R&D lab in our sample can perform more than one activity. For example, only one third of the 32% of
labs carrying out biotechnology research perform only biotechnology research. The other two thirds perform
research in biotechnology and in one or more other chemical sectors.
7 For example, in Denmark, Finland, Ireland, and the Netherlands, the percentage of chemical R&D labs doing
biotechnology research is respectively 48.5%, 49.4%, 40.4%, and 42.0%. By contrast, the percentage for Italy,
Germany, and France, is 21.0%, 25.1%, 30.7%. In the UK, the percentage is 39.5%. This confirms that
biotechnology offers an opportunity for entry in the broadly defined chemical industry to countries that were not
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Netherlands. The former two countries are above, while the latter are below the
sample average. It appears, therefore, that the entry of Finland and Ireland is related
to public funding and public research in biotechnology. By contrast, in the
Netherlands, and partly in Denmark, the share of activities in biotechnology is to a
greater extent associated with private research. No single model emerges. Either
private or public research can be the means by which newcomer countries can focus
on biotechnology.
Home vs. foreign locations of the inventive activity in biotechnology
The data provide information on the extent to which patent assignees locate research
activity in their home country. It is assumed that the locus of the innovative activity
is the location of the inventors of the patent and that the location of the patent
assignee is given by the nationality of the ultimate owner of the assignee8. The
results show that, in general, the home country is the preferred location of inventive
activities in all countries and sectors, and that biotechnology is a partial exception,
with the European countries locating a significant share of their inventive activity in
the US.
                                                                                                                                         
leaders in traditional chemicals. The long standing dominance of Germany and the UK, and partly of Italy and
France, in chemicals does not seem to provide a critical advantage in the new biotechnology industry.
8 The need to control for the ultimate owner of the assignees was the reason why the smaller sample of 10,000
patents was used here. It would be very difficult to examine the complete sample of 97,785 patents for the
purpose of this Report.
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Table 2.4: Share of patents by region of the assignee, region of the inventor and by
sector (10,000 sample patents).
Country of the assignee
Country of the inventor EU US Total
All chemical sectors
EU 86.3 % 9.0 % 44.8 %
US 11.9 % 87.8 % 34.5 %
Total 98.2 % 96.8 % 79.3 %
Biotechnology
EU 82.1 % 4.9 % 36.5 %
US 14.6 % 92.7 % 45.4 %
Total 96.7 % 96.6 % 81.9 %
Materials
EU 90.7 % 8.0 % 44.9 %
US 7.8 % 90.1 % 30.9 %
Total 98.5 % 98.1 % 75.8 %
Organic chemistry
EU 89.1 % 10.8 % 50.8 %
US 9.5 % 87.4 % 28.4 %
Total 98.6 % 98.2 % 79.2 %
Pharmaceuticals
EU 85.0 % 11.5 % 47.3 %
US 13.3 % 86.2 % 36.0 %
Total 98.3 % 97.7 % 83.3 %
Polymers
EU 85.4 % 8.3 % 40.1 %
US 12.9 % 84.6 % 33.5 %
Total 98.3 % 92.9 % 73.6 %
Source: European Patent Office (1998)
Table 2.4 shows that European assignees invent 86.3% of their chemical patents in
Europe and US assignees 87.8% of their patents in the US.
When European companies locate their patenting activity outside Europe, they
develop almost all of their “foreign” chemical patents in the US − the total share of
patents by European assignees invented either in Europe or in the US is 98.2%. Thus,
the US is the favourite foreign location of the European assignees. Finally, there
seems to be a fairly balanced interchange of research between the two continents in
chemicals since the share of EPO patents by European assignees invented in the US
(11.9%) is very close to that of the EPO patents by US assignees invented in Europe
(9.0%).
As shown also in Table 2.4, this pattern of cross-location between Europe and the US
is also similar across the chemical subsectors, with biotechnology being the only
exception. The result that really stands out is the share of biotechnology patents by
US assignees invented in Europe, which is only 4.9%, while the share in the other
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direction is 14.6%, suggesting that the US is an attractive location for biotechnology
research by European assignees.
Therefore, the data do not show that European assignees perform a
disproportionately large amount of biotechnology research in the US – they do
almost as much biotechnology research in the US as they do in the other chemical
sectors – but that Europe is not attracting similar levels of biotechnology research
performed by US assignees. Even in pharmaceuticals, which is the closest to
biotechnology, Europe attracts 11.5% of the patents applied for by US assignees. The
apparent European lack of attractiveness to US research seems to be specific to
biotechnology.
Table 2.5 shows the shares of biotechnology patents invented by European assignees
in their home country, in the US, and in European countries other than the home
country. The Table shows that the assignees locate research largely in their home-
country, although inter-country differences exist. The most important difference is
that Swiss assignees invent almost half of their biotechnology patents in the US,
while assignees from all the other countries in Table 2.5 (Germany, France, Italy, the
Netherlands, and the UK) invent over 70% of their biotechnology patents at home.
Apart from the US, the latter countries have a sizeable share of biotechnology patents
invented in other European countries and, moreover, these patents are not
concentrated in the leading nations – Germany or the UK – but are spread across
European countries. When Swiss multinationals are excluded from the sample, the
share of biotechnology patents by European assignees invented in the US declines
from 14.6% to 11.3%. This is more aligned with the analogous share for the other
chemical sectors presented in Table 2.4.
Table 2.5: Share of biotechnology patents invented by European assignees in the
home country, in the US and in other European countries (10 000 patents in 1987-
1996)
Country of the assignee
Switzerland Germany France Italy Netherlands UK
Patents invented
in the home country 30,6 76,2 81,5 73,3 70,7 76,9
Patents invented
in the US 48,2 7,6 11,0 4,9 4,4 8,1
Patents invented in the
other EU countries 18,4 11,2 4,2 21,8 24,8 12,8
Source: European Patent Office (1998)
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II. 4 Summary of Results
The main findings of this section can be summarised as follows:
The USA have accumulated and maintain a large absolute advantage in innovative
activities in biotechnology vis-à-vis Europe.
The USA are more specialised in biotechnology research compared to Europe and
Japan. However, some of the smaller European countries (particularly Ireland,
Denmark, the Netherlands and the Scandinavian countries) are also focused on
biotechnology.
Either private or public research can be the means by which newcomer countries can
enter biotechnology research, and no single mode has emerged.
The share of biotechnology patents invented in the US and assigned to European
organisations is higher than that of the other chemical sectors. This suggests that the
US are an attractive location for biotechnology research conducted by European
organisations.
The share of biotechnology patents invented in Europe and assigned to US
organisations is particularly small, and much smaller than the analogous share for the
other chemical sectors.
A key finding of the Report is therefore the lack of attraction of US biotechnology
research by Europe rather than the European research investments in the US.
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III. Division of Innovative Labour and Markets for Technology
III.1 Introduction
The growth of technological opportunities and the relevance of scientific research for
innovative activities associated with molecular biology and biotechnology has
promoted the emergence of a vibrant market for technology (see Arora, Fosfuri, and
Gambardella, 2001; Arora, Gambardella, Pammolli, Riccaboni, 2001).
The ability of firms to access and make efficient use of markets for technology and
networks of collaborative relations has become a crucial source of competitiveness.
As a consequence, in the last 25 years collaborations in biotechnology have increased
dramatically, worldwide (Orsenigo, Pammolli, Riccaboni, 2001).
Most DBFs exploit their basic competences and act primarily as research companies
and specialised suppliers of high technology intermediate products, performing
contract research for, and in collaboration with, established corporations in
downstream sectors. Collaboration allows DBFs to survive and – in some cases – to
pave the way for subsequent growth. First, clearly, collaboration with large
companies provides the financial resources necessary to fund R&D. Second, it
provides the access to organisational capabilities in product development and
marketing.
The latest generations of DBFs (and the new “stars” like Affymax, Incyte and
Celera) were created on the basis of specialisation into radically different new
technologies like genomics, combinatorial chemistry, bioinformatics and what is now
called “platform technologies”. These technologies are essentially research tools and
their developers do not aim to become producers but rather providers of tools and
services to corporations involved in drug discovery and development. They may thus
be able to sell customised services to a wider range of potential buyers.
Established companies face the opposite problem. While they need to explore,
acquire and develop new knowledge, they have the experience and the structures
necessary to control testing, production and marketing. Faced with an explosion of
the space of innovative opportunities, no individual company, irrespective of its size,
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can even think to be able to successfully originate and control all the  relevant
knowledge.  Thus, participation in the network of collaboration and in markets for
technology becomes a crucial ingredient for sustained technological and economic
performances.
Assessing the involvement of European firms and institutions in these networks is
therefore a crucial exercise for an evaluation of the status of the European
biotechnology industry.
III.2 Research Teams in Biotechnology Patents: Geographical vs.
Organisational Proximity as Coordination Mechanisms
Collaborations across assignees
A review of the patents with multiple assignees shows that in biotechnology the
share of patents assigned to multiple assignees is higher than in the other sectors. On
the basis of the 10,000 patent sample, there are 11.2% biotechnology patents with
multiple assignees as against 8.9% in pharmaceuticals, 5.4% in organic chemistry,
3.8% in polymers, and 3.1% in materials9. Biotechnology appears to be more open to
collaboration.  This is so even when it is compared to pharmaceuticals, which is
technologically closer to biotechnology and is a more collaborative field (8.9%
multiple assignee patents) than the other fields in traditional chemicals. Furthermore,
the evidence suggests that there are no country–specific factors that could account
for this.
Collaborations among inventors
Single inventors develop only 18.3% of the sample’s 97,785 chemical patents, while
the remainder (81.7%) are developed by two or more inventors. Hence, while there
are few patents with multiple assignees, there is a great deal of collaboration among
individuals. These teams of inventors are mostly national. Overall, 90.8% of the
                                                
9 Overall in our sample of 10,000 patents, the share of single assignees is 93.2%, for the same as in the 97,785
sample. This is suggestive of the comparability of the statistics computed by using either of the two samples. In
this case, we are using the 10,000 sample because, as we shall see below, we need to use the information on the
country of origins of the ultimate parent of the assignees.
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patents in the sample developed by multiple inventors are among individuals from
the same country.
To review further the question of the nature and characteristics of research teams in
biotechnology patents a sub–sample of 4,649 patents from the EPO sample of 10,000
patents was selected on the basis of having at least one inventor located in Europe.
The focus on inventions carried out in Europe is related to the finding that Europe
does not appear to be a very attractive location for biotechnology research. It is
therefore interesting to understand in greater depth the characteristics of the research
located in it.
The data show that single inventors develop 788 patents (16.9%) and multiple
inventors the remainder  (83.1)%. In addition, there is no major difference across
countries or sectors in the size of the research team.
Table 3.1 reports the average number of supplementary classes of these patents.
Again, this is broken down by sectors and by some leading countries. As  is evident,
biotechnology patents by US assignees that were invented in Europe have a
significantly higher degree of interdisciplinarity compared to biotechnology patents
by the other countries in the table (Germany, France, and the UK). This suggests that
the US assignees patent in Europe research outputs with a greater degree of
generality compared to the others, the difference being particularly striking with
Germany. The average number of IPC classes in German biotechnology patents
invented in Europe is 1.8, compared to 2.7 for the US. The figures for France and the
UK are respectively 2.4 and 2.5.
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Table 3.1: Mean number of supplementary classes by patent. Inter-country (country
of the assignee) and inter-sectoral differences
Sectors DE FR UK US TOT
Biotech 1.8(0.17)
2.5
(0.18)
2.4
(0.18)
2.7
(0.3)
2.1
(0.08)
Materials 1.02(0.19)
1.2
(0.31)
1.5
(0.38)
1.5
(0.54)
1.3
(0.13)
Organic chemistry 2.4(0.07)
2.4
(0.13)
2.7
(0.15)
2.9
(0.21)
2.5
(0.05)
Pharma 1.7(0.09)
1.2
(0.13)
1.5
(0.14)
1.2
(0.2)
1.6
(0.06)
Polymers 1.8(0.09)
1.5
(0.19)
1.7
(0.23)
1.6
(0.26)
1.7
(0.07)
Average by country 2.0(0.05)
1.8
(0.09)
2.0
(0.09)
2.3
(0.12)
2.0
(0.03)
Standard errors in parentheses.
Source: Our elaboration from the EPO data.
The higher interdisciplinarity of the US biotechnology patents might reflect the fact
that for the US assignees, patents in Europe are inventions patented abroad. Since
patenting abroad is more costly, one may patent abroad only the more important
patents, which are likely to be the more interdisciplinary ones. But Table 3.1 shows
that US biotechnology patents are relatively more interdisciplinary compared to other
countries than the US patents in the other chemical sectors. For example, even in
pharmaceuticals, which is the sector closest to biotechnology, the average number of
IPC classes of the US patents is 1.2 vs 1.7 for Germany, 1.2 for France, and 1.5 for
the UK. This suggests that the US biotechnology patents invented in Europe may
indeed be more general. If so, this would indicate that US biotechnology research in
Europe plays a beneficial role, as US assignees are more likely to perform
interdisciplinary research that tends to lead to more valuable inventions than
European assignees (see Trajtenberg, 1990).
As for geographical proximity of inventors, data show that the share of Delocalised
biotechnology patents (DL)10 over the total number of biotechnology patents in the
                                                
10 The address of the inventors listed in each patent was used to attribute its  location to a given NUTS1 or
NUTS2 European region. A patent is defined to be Colocalised (CL) if all the inventors are located in the same
region. If at least one of them is located in a different region, the patent is classified as Delocalised (DL).
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sample of European inventions is 40.9%. Colocalised patents (CL) are 59.1%11.  The
relatively high share of CL patents suggests the importance of geographical
proximity among inventors. Moreover, the research teams of DL patents involve a
significantly higher number of inventors than CL patents. The size of the teams in
DL patents is on average 4.1, while for CL patents it is smaller by 1.7 units12. That is,
DL patents involve larger teams.
However, DL patents do not imply a significantly higher number of IPC classes per
patent. Biotechnology patents that list inventors located in different regions entail
larger teams, but they are not more general than those developed by inventors who
are all located in the same region.
Moreover, the share of the DL patents developed by US assignees is higher than the
share of the DL patents of any other country13. According to the data, the share of
DL biotechnology patents  in the total sample of US biotechnology patents is 70.4%.
This figure is higher than that of the US in all the other chemical sectors. Moreover,
DL biotechnology patents with US assignees mainly correspond to collaborations
across European regions. This suggests that US assignees doing biotechnology
research in Europe are an important vehicle for inter-regional collaboration,  doing
more of it  than the assignees by the European countries, and more than  the US
assignees themselves do in other chemical sectors.
Finally, there is evidence that large firms are less involved in interdisciplinary
biotechnology14. The analyses reveal that compared to the other four chemical
sectors, biotechnology patents exhibit a much higher share of patents by smaller
firms (Non Fortune 500). About 75.5% of the biotechnology patents go to such
firms, while the share for the other sectors ranges between 44.7% and 58.2%. This
finding is consistent with the existing literature on the industry, which has stressed
                                                
11 These include 18% patents with only one inventor. We included the single inventor patents in CL because we
are interested in the search for competencies outside of the region or cluster. Individual inventors did not team up
with others, and hence they seemed to have no need (or opportunity) to reach outside of their region.
12 The teams in the CL patents might be smaller because they include the single inventor patents. However, when
excluding the latter, the CL patents were still significantly smaller than the DL patents by 1.3 units.
13 This is not surprising, since the sample includes only US patents with at least one inventor located in Europe.
Hence, it does not consider the CL patents developed by the US assignees in the US.
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that competencies for producing innovations with greater breadth (and value) tend to
be associated with smaller academic labs and research-intensive firms (e.g. see
Gambardella, 1995). In other words, it is the quality of the team, rather than the size
of the organisation, that matters in this case. Moreover, research in biotechnology
appears to be internationalised, with its knowledge foundations being developed on a
“global” basis.
                                                                                                                                         
14 A distinction between Fortune 500 and Non Fortune 500 firms was made. Overall, these firms cover a very
large fraction of the patents in the sample  (4,320 out of our 4,649).
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III. 3. The Network of Collaborative Relations
Table 3.2 shows the nationality of origin and development of collaborative
agreements (CA) in biotechnology for selected years. A crucial difference between
Europe and the US becomes immediately apparent. The overwhelming majority of
the biotechnology collaborative projects originates (70,07%) and is developed
(66,12%) in the US. However, European biotechnology organisations have
progressively increased their role both as originators (from about 14% in 1990-94 to
about 20% in 1998-00) and as developers (from 12.46 to 21.61%) of new projects.
Table 3.2: Number of Organizations and Number of Originated and Developed
Collaborative Agreements (CAs) in Biopharmaceuticals, by Nationality:1990-1994,
1995-1997, 1998-2000
Number of Organizations Number of CAs
EFs DBF s PRO s as Originators as DevelopersNationality Total
Num. (%) Num. (%) Num. (%) Num. (%) Num. (%)
1990-1994
EU15 112 41 36,61 36 32,14 35 31,25 274 14,05 243 12,46
USA 496 154 31,05 241 48,59 101 20,36 1 463 75,03 1459 74,82
Japan 25 23 92,00 1 4,00 1 4,00 65 3,33 84 4,31
Other 93 31 33,33 36 38,71 26 27,96 148 7,59 164 8,41
Total 726 249 34,30 314 43,25 163 22,45 1950 100,00 1950 100,00
1995-1997
EU15 226 89 39,38 95 42,04 42 18,58 510 17,90 553 19,41
USA 652 196 30,06 338 51,84 118 18,10 1989 69,81 1830 64,23
Japan 47 41 87,23 6 12,77 0 0,00 61 2,14 173 6,07
Other 195 59 30,26 73 37,44 63 32,31 289 10,14 293 10,28
Total 1120 385 34,38 512 45,71 223 19,91 2849 100,00 2849 100,00
1998-2000
EU15 447 117 26,17 223 49,89 107 23,94 838 20,19 897 21,61
USA 1124 334 29,72 587 52,22 203 18,06 2819 67,91 2629 63,33
Japan 81 64 79,01 8 9,88 9 11,11 119 2,87 212 5,11
Others* 313 78 24,92 151 48,24 84 26,84 375 9,03 413 9,95
Total 1965 593 30,18 969 49,31 403 20,51 4151 100,00 4151 100,00
1990-2000
EU15 785 247 31,46 354 45,10 184 23,44 1622 18,12 1693 18,92
USA 2272 684 30,11 1166 51,32 422 18,57 6271 70,07 5918 66,12
Japan 153 128 83,66 15 9,80 10 6,54 245 2,74 469 5,24
Others* 601 168 27,95 260 43,26 173 28,79 812 9,07 870 9,72
Total 3811 1227 32,20 1795 47,10 789 20,70 8950 100,00 8950 100,00
*Argentina, Australia, Bermuda, Brazil, Canada, China, Costa Rica, Croatia, Cuba, Czech Republic,
Egypt, Hong Kong, Hungary, Iceland, India, Indonesia, Israel, Malaysia, Mexico, New Zealand,
Norway, Philippines, Poland, Puerto Rico, Russia, Singapore, Slovenia, South Africa, South Korea,
Switzerland, Taiwan, Thailand, Yugoslavia.
EFs: established firms; DBFs: dedicated biotechnology firms; PROs: public research organisations
Source: BID, University of Siena.
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In the second part of the 1990s the number of DBFs rose in Europe but remained
substantially unchanged in the US (see below). European DBFs are still
proportionately less integrated than US DBFs in the networks of division of
innovative labour:  68% of all collaborative agreements originate in the US,
compared with only 20% that originate in the EU (see Table 3.2). Age is not the only
factor underlying the lower participation of European DBFs in markets for
technology. Some structural differences between Europe and the US affect the
collaborative capabilities of DBFs.
American DBFs develop a larger share of projects originated by domestic public
research organisations (PROs) and DBFs and by European DBFs than European
counterparts. In Europe, DBFs tend to be substituted as developers by established
companies. Interestingly enough, the only exception is for projects originated by
European PROs, which are developed mainly by co-localised DBFs or by European
PROs.
European PROs have increased their relationships with both European and American
DBFs in 1996-2000. On the contrary, US-based PROs collaborate more and more
directly with established companies and act more frequently as developers of projects
originated by DBFs. In general, universities and research institutes increasingly reach
out and collaborate with delocalised partners both as originators and as developers.
European DBFs do not seem to be able to attract US established pharmaceutical
companies as developers of projects originated in Europe, and they turn
preferentially to European partners.
Only a minority of European DBFs in Europe participates as developers in
collaborative projects originated by other organisations. Established companies have
the lion’s share of bio-pharmaceutical products in Europe.
Moreover, (see Arora, Gambardella, Pammolli, Riccaboni, 2001), European
companies tend to access markets for technologies later on during product
development (clinical research and marketing),  and are less active in the early stages
of research. Product innovation in therapeutic biotechnology is highly dependent on
both the originator and developer capabilities of US companies. European DBFs, still
young and small, do not take part in the division of innovative labour in product
development, particularly with American PROs and established companies.
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Finally, PROs in Europe tend to be focused on the generation of new research
opportunities, while they tend to be absent from the downstream stages of product
development.
III.4. Summary and Conclusions
The main findings of this section can be summarised as follows:
First, markets for technology and networks of collaborative agreements are important
in biotechnology.
Second, the biotechnology patents by US assignees invented in Europe are more
interdisciplinary than those of the European assignees. This finding is specific to
biotechnology and suggests that they are also potentially more valuable.
Third, US biotechnology patents developed in Europe are the outcome of teams of
inventors located in different regions, whether different NUTS European regions, or
Europe and the US. This suggests that US biotechnology patents enhance
international and inter-regional collaboration in Europe.
Fourth, small firms produce a large amount of inventions in biotechnology.
Fifth, the network of the biotechnology collaborative projects is largely US based,
despite a recent increase in the participation of European biotechnology
organisations. European DBFs tend to be less active in the networks and they do not
seem to be able to attract US established pharmaceutical companies as developers of
projects originated in Europe. Rather, they  turn preferentially to European partners.
Sixth, PROs in Europe tend to be focused on the generation of new research
opportunities, while they tend to be absent from the downstream stages of product
development. Moreover, European companies tend to access markets for
technologies in biopharmaceuticals later on during product development (clinical
research and marketing), and they are less active in the early stages of research. In
synthesis, product innovation in biopharmaceuticals is highly dependent on the
capabilities of US companies.
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IV.  The New European Biotechnology Industry15
IV. 1. Introduction
It was suggested in the previous section that European biotechnology is lagging
significantly behind the US. However, encouraging signals related mainly to the
good performance of some small (mainly northern) European nations and to an
impressive recent increase in the number of DBFs was also stressed. This section
examines the characteristics of European DBFs.
DBFs are widely considered to be the most efficient available organisational solution
for the development of innovative activities in biotechnology.
First, DBFs are fundamental organisational devices for exploring an enormous,
quickly expanding and incredibly complex space of new innovative opportunities. In
a context of rapid and tumultuous technological advance, where knowledge is still
fragmented and dispersed, no single institution is able to generate and develop all the
necessary ingredients for discovering and bringing new products to  the marketplace
(see Powell, Koput, Smith-Doerr, 1996; Orsenigo, Pammolli, Riccaboni, 2001).
Second, the DBFs perform a crucial function by transforming scientific knowledge
into technological and commercial applications. They intermediate in the transfer of
knowledge from universities to established large corporations that cannot be always
at the forefront of scientific discovery but have the downstream capabilities needed
for commercialisation (Orsenigo, 1989; Henderson, Orsenigo and Pisano, 1999).
Third, DBFs promote and are crucial agents in markets for technology and division
of innovative labour  (Arora, Gambardella, 1994; Gambardella, 1995; Arora,
Gambardella, Pammolli, Riccaboni, 2001), in the context of a system in which
control rights can be allocated to maximise innovative output in conditions of
incomplete contracting (Lerner and Merges, 1998).
                                                
15 This section is based on Pammolli and Riccaboni, 2001.
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IV. 2  The Database
The analysis in this section is based on the Biotechnology Industry Database (BID)
built up by the EPRIS Group at the University of Siena16. BID includes a wide range
of information concerning European organizations active in biotechnology
innovation and production systems. BID provides a full-fledged set of information on
the state of the industry, up to the end of year 2000. In particular, it integrates a
comprehensive set of sources of information to provide an articulated representation
of the variegated factors and players that take part in  European biotechnology.
Organizations have been identified by referring to:
1) Descriptions of core business, technological background, and fields of
applications. Such information is voluntarily provided by biotechnology
organizations through Internet sites, specialized press, venture capitalists,
and participation in  public surveys or biotechnology and regional
associations. Furthermore, the analysis builds upon information from
commercial directories (i.e. Pharmaventure, Bioscan, BioCommerce,
Windhover, Recap, Scrip) and by means of an Internet survey
(www.eprisproject.com/eubio);
2) Records of research and production activities. Even though small
biotechnology companies might sometimes be secretive about their
innovative efforts, information on R&D activities tends to leak out in the
public domain. In particular, publications, patents, collaborative
alliances, pharmaceutical and agricultural trials, participation in national
and EU biotechnology programs, and quotation on public stock markets
provide an unequivocal trace of active biotechnology companies.
Research and industrial activities have been monitored by accessing and
integrating multiple (both public and proprietary) sources of information.
In addition, members of European and national biotechnology
associations and, moreover, all the companies that monitored in BID,
                                                
16 The Epris Group at the University of Siena includes: Fabio Pammolli (Director), Massimo Riccaboni
(Coordinator), Gianluca Baio, Rossana Pammolli, Daniela Casula, Carmela Pace and Antonella Fiore (Research
Assistants). Alberto D’Amico, Chiara Giani, Andrea Paolini and Pietro Bubba Bello, (Industrial Liaison Office,
University of Siena) provided a generous organisational support.
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were asked to provide information on their in-house R&D projects and
on collaborative agreements.
The analysis of the structure and evolution of innovation and production systems in
biotechnology is particularly complex, for the following reasons:
(a) The lack of a general and commonly accepted definition of biotechnology affects
the reliability and the comparability of official analyses and statistics, making any
measurement extremely difficult. Historically, the definition criteria adopted from
different national and international sources have been heterogeneous. The report
adopts  the definition of biotechnology developed by the OECD (see van Beuzekom,
2001). This definition focuses on techniques (tools, manipulation and know-how)
that either modify existing living organisms/part of them, or transform material, of
living origin or not, by the use of processes involving living organisms, for the
purpose of producing new (scientific) knowledge or developing new products or new
processes.
The following classification is referred to:
• DNA (the coding): genomics, pharmaco-genetics, gene probes, DNA
sequencing/synthesis/amplification, genetic engineering;
• Proteins and molecules (the functional blocks): protein/peptide
sequencing/synthesis, lipid/protein engineering, proteomics, hormones, and
growth factors, cell receptors/signalling/pheromones;
• Cell and tissue culture and engineering: cell/tissue culture, tissue engineering,
hybridisation, cellular fusion, vaccine/immune stimulants, embryo
manipulation;
• Process biotechnology: Bioreactors, fermentation, bioprocessing, bioleaching,
bio-pulping, bio-bleaching, biodesulphurisation, bioremediation, and
biofiltration;
• Sub-cellular organisms: gene therapy, viral vectors.
In addition to ‘core’ biotechnology organisations identified according to the OECD
definition, the report takes into account those firms which are focused on the
development of tools, instruments, and devices that apply directly and prevalently to
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biotechnology product development, such as bioinformatics, highthroughput
screening, combinatorial and chiral chemistry.
(b) Most of the dedicated biotechnology organizations, especially in Europe, are so
young and small that they do not show up in any survey. They are  deeply involved
in set up and early-stage R&D activities that do not provide any externally visible
signal, be it a scientific board, a deal, or a first-round of financing. Aware of that,
both strategy 1 and 2 were implemented for all the European countries, trying to
reduce the black area of unobserved biotechnology activity.
(c) A third limitation of currently available statistics is a consequence of the fact that
organisations active in biotechnology are typically heterogeneous and embedded in
complex proprietary and collaborative networks. They range from public research
organisations (universities, hospitals, research labs, foundations, and institutes), to
large pharmaceutical, agro-chemicals, food and chemical companies (typically,
highly diversified multinationals with several divisions and intricate proprietary and
control links). Dedicated biotechnology firms (DBFs) play a pivotal role in
connecting heterogeneous components and actors. As a result, boundaries among
different organizations are often evanescent and it becomes hard to count the number
of independent units. In order to take into account the existence of these complex
systems of innovation, production, and control, the organisations monitored in the
survey have been classified according to four main categories:
Independent dedicated biotechnology firms (DBFs): i) core biotechnology firms:
European private and public firms specialised in biotechnology product and process
development; ii) specialised suppliers, e.g. firms active in combinatorial chemistry,
bioinformatics, DNA sequencing instrumentation, and in the production of tools and
techniques which are used by ‘core’ biotechnology companies.
Established companies active in related fields (ECs): large companies that do have a
sound research position in modern biotechnology. Although the core business of
firms in this category is not in biotechnology, they are actively involved in
biotechnology research and development;
Biotechnology divisions: units that operate in biotechnology and are controlled either
by established companies or by DBFs;
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Public Research Organizations (PROs): research institutes, universities, hospitals
and other public organizations with relevant scientific results in molecular biology
and in  fields and disciplines related to biotechnology.
IV. 3. The Structure of the Industry
This section uses data from the Biotechnology Information Databank (BID),
maintained at the University of Siena, which includes 3669 organisations active in
biotechnology (see also Pammolli and Riccaboni, 2001).
Among them, there are 2092 independent dedicated biotechnology firms (DBFs).
More specifically, there are 1730 core biotechnology firms (according to the OECD
classification) and 362 specialised suppliers. Detailed data for each of these has been
collected17.
Localisation of European DBFs
Figure 4.1 shows the number of independent dedicated biotechnology firms in major
European countries at the end of year 2000. Figure 4.1 does not consider public
research organisations, companies whose main activities are in fields other than
biotechnology,  or biotechnology divisions of larger firms. They represent the ‘inner
core’ of the European national systems of innovation in biotechnology. According to
the data collected in BID, Germany leads the league with more than 500 small
independent dedicated biotechnology firms (DBFs), followed closely by the UK.
Taken together, Germany and the UK account for about one half of the total number
of DBFs in Europe. France ranks third with 343 biotechnology companies, followed
by Sweden.
If one calibrates the number of DBFs using population or GDP numbers (Table 4.1),
a clear representation emerges, with Sweden ranked first according to both measures,
                                                
17 For each firm, the following information was collected: name, type of organization, business description,
location, year of establishment, major historical events (such as date of starting of biotechnology activities and
M&As), main financial data (when available), employees, fields of activity, technological background, patents,
collaborations, R&D projects
33
followed by Switzerland, Ireland, Finland, and Denmark. The UK, Germany and
France have similar values while Italy and Spain have the lowest ratios.
Figure 4.1: Number of Independent DBFs, Main European Countries (Dec. 2000)
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Figure 4.2 characterises European biotechnology innovation and production systems
in terms of the types of active organizations. There are important differences in the
composition of the industry across European countries. In particular, the UK and, to
a lesser extent, France, differ from Germany, both because of the high number of
divisions of companies focused on biotechnology, and because of the higher number
of large firms. Moreover, in the UK one can observe a higher number of non-
industrial research institutes in the fields of molecular biology and biotechnology. In
Italy and Spain the number of DBFs is particularly low when compared to the
number of large firms or of divisions of large firms.
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Figure 4.2 Number of Organizations Active in Biotechnology, by Type (Dec. 2000)
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 (Dec.2000)
Number of GDP DBFs per
DBFs (EURO Thousands) Inhabitants
Country (1) (2) (3) (1/2) (1/3)
Sweden 235 9052 37750127 0,02596 0,006225
Switzerland 93 7374 12444024 0,01261 0,007473
Ireland 39 3493 19875805 0,01117 0,001962
Finland 53 5115 42337212 0,01036 0,001252
Denmark 51 5320 213290714 0,00959 0,000239
Norway 37 4461 28201643 0,00829 0,001312
United Kingdom 448 59247 230860181 0,00756 0,001941
France 342 58816 346953663 0,00581 0,000986
Germany 504 85684 25433691 0,00588 0,019816
Belgium 55 10286 40219969 0,00535 0,001367
Netherlands 79 15893 59744161 0,00497 0,001322
Austria 11 8124 88226106 0,00135 0,000125
Italy 64 57807 189869364 0,00111 0,000337
Spain 32 39545 34198374 0,00081 0,000936
Source: BID, University of Siena
Table 4.1. Number of DBFs per Inhabitant and National GDP
Inhabitants/1000 DBFs/GDP
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The dynamics of entry
Figure 4.3 shows the distribution of European DBFs by year of foundation. Peak
years of entry were 1997 and 1998. In 1999 and 2000, after a 4-year period of intense
entry, in which the overall number of EU biotechnology firms almost doubled, the
rates of company formation decreased. This slowdown  (not corroborated by Ernst &
Young’s data) seems to be similar, in nature, to the one observed in the USA at the
beginning of the Nineties and it could anticipate a period of stabilisation,
consolidation, and selection, with mergers, acquisitions, and exit offsetting new
company formation. As a consequence, the impact of the intense entry on the long-
term evolution of the industry is not known, and the industry seems to be far from
any equilibrium configuration.
Figure 4.3. European Dedicated Biotechnology Firms: Distribution by
Year of Foundation (firms per year)
Source: Pammolli and Riccaboni, 2001, based on BID, University of Siena
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Table 4.2 and Figure 4.4 show the distribution of dedicated biotechnology companies
in Europe, by cohorts of entrants. It is clear that there are important differences in
terms of the generational composition of DBFs in major European countries. Nordic
countries like Sweden have experienced a relatively stable pace of entry of new
firms, while in other countries, particularly Germany, the upsurge of the number of
new firms has occurred in the last five years. At present, Germany accounts for a
third of the total number of new European firms (i.e. those which entered the
industry after 1995), followed by UK and France. The three countries, taken
together, account for more than ¾ of the new biotechnology firms that entered the
industry between 1996 and 2000, with numbers well above the EU–15 average.
Table 4.2 European Dedicated Biotechnology Firms: Distribution by Cohorts of
Entrants
EU15 United Kingdom Germany France Sweden Others*
Nr % Nr % Nr % Nr % Nr % Nr %
<=90 600 31,09 147 32,81 102 20,24 112 32,18 89 37,87 150 37,9
91-95 487 25,23 113 25,22 114 22,62 86 24,71 61 25,96 113 28,6
>=96 843 43,68 188 41,96 288 57,14 150 43,10 85 36,17 132 33,4
Total 1930 100,00 448 100,00 504 100,00 348 100,00 235 100,00 395 100,0
*Others: Austria, Belgium, Denmark, Finland, Ireland, Italy, Luxembourg, Netherlands, Portugal, and Spain
Source: Pammolli and Riccaboni, 2001, based on BID, University of Siena.
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Figure 4.4. European Dedicated Biotechnology Firms: Patterns of Entry, Main
Countries
Source: Pammolli and Riccaboni, 2001, based on BID, University of Siena
Size
Figure 4.5 shows the size distribution of European DBFs, in December 2000, divided
into classes according to the number of employees. As  is evident, most European
DBFs are either micro or small, research-intensive firms. Only approximately 10
percent of active European DBFs have more than 50 employees, while the vast
majority (about 57 per cent) have fewer  than 20 employees. It is worth noting that
despite general similarities in the shape of business size distributions, European
national systems of innovation in biotechnology rely on quite different mixtures of
small and medium biotechnology companies. Surprisingly enough, if compared with
general figures about  firm size in manufacturing, the size of French DBFs is well
above the mean for EU-15, while the opposite it is true for Sweden. Moreover, while
UK and Germany look similar in terms of shares of micro business units over the
total number of firms active in biotechnology, Germany has a higher proportion of
firms in the middle size range (10 to 50 employees)  than the UK, which relies upon
a higher number of medium and large DBFs.
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Sectoral composition and areas of specialisation
The sustained flow of entry shown above has changed the relative importance of
agro–food and pharmaceuticals as areas of application (see Figure 4.6). The
proportion of new DBFs that entered the agro-food industries declined from 1995,
from about 15% to less than 5% in the year 2000; this fall probably reflects
regulatory factors and growing public opposition to genetically-modified crops.
During this time, the number of dedicated bio-pharmaceutical companies rose  from
35% to more than 50 % of the total number of new firms. Thus, the dramatic increase
in the number of European DBFs from 1996 to 2000 reflects, to a large extent, a flow
of new DBFs that entered the industry to exploit the therapeutic applications of
genomics and new techniques, such as combinatorial chemistry and bio-informatics,
which can be used to improve and speed up the development of new therapeutic
treatments (see Pammolli and Riccaboni, 2001).
Figure 4.5. European Dedicated Biotechnology Firms: Distribution of Employment by
Size Classes
Source: Pammolli and Riccaboni, 2001, based on BID, University of Siena
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Figure 4.6. Proportion of European DBFs Active in Human Therapeutics and
Agriculture, by Year of Foundation
 Source: Pammolli and Riccaboni, 2001, based on BID, University of Siena
Table 4.3 summarises the technological profiles of EU DBFs according to broad
areas of interest in biology, chemistry and medicine. It shows the existence of
differences among European countries concerning the areas of specialisation of
national DBFs in main fields of application. German biotechnology companies are
active mainly in human health care (therapeutics and diagnostics), Swedish firms
concentrate on human and animal therapeutics, while France, Italy, and Switzerland
have a higher proportion of companies active in agro-food. A large proportion of
French and German DBFs entered the industry, both in pharmaceuticals and agro-
food, to explore the commercial value of recent technological advances at the lowest
levels of organisation of living organisms in genomics, proteomics and
bioinformatics. The UK keeps a strong technological basis in cell and tissue
engineering, process biotechnology, instrumentation, and devices. Moreover, new
UK DBFs are more active in combinatorial chemistry and in other general–purpose
research techniques applied to drug discovery and development. Italy’s specialisation
is in targeting sub–cellular organisms, while Swedish companies tend to focus
mainly on manufacturing biomaterials and on innovative technologies in drug
discovery, such as combinatorial chemistry and chiral synthesis.
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Finally, Table 4.4 shows the extent to which biotechnology applications and research
technologies are integrated at the firm level, in key European countries. French and
British companies have the highest degree of integration between technologies and
applications. The higher level of integration of UK firms could well reflect a
difference in the composition of industry in terms of cohorts of entrants, since the
UK has a higher fraction of early entrant DBFs, which had sufficient time to
implement their technologies in specific domains of application. On the contrary,
German and, particularly, a significant fraction of Swedish firms, tend to be
vertically specialised either in terms of technologies or domains of application.
Source: Pammolli and Riccaboni, 2001, based on BID, University of Siena
Figure 4.7 shows the effects of patterns of technological change on national profiles
of specialisation. In the second half of the Nineties, new technologies have emerged,
particularly in the field of DNA coding, which have promoted the application of
advanced computational methods and technologies (such as bio-informatics, and
high throughput screening) to R&D.  Proteins, monoclonal antibodies, and enzymes
continue to characterise the technological background of many European DBFs,
especially in France, where the application of enzymes to agro-food also plays an
important role, and in Nordic countries, where the wool, pulp, and paper industries
have increased the use of enzymes and bacteria to develop new products and
Table 4.4. European Dedicated Biotechnology Firms: Distribution by Technological Fields 
 
Country 
Cell and 
Tissue 
Culture and 
Engineering 
Subcellular 
Organisms DNA  
Proteins and 
Molecules 
Process 
Biotechnology
Chemical 
Synthesis1 Bioinformatics
Other 
Devices2 Analysis3 Total 
  Num. % Num. % Num. % Num. % Num. % Num. % Num. % Num. % Num. %Num. %
EU 15 436 18,72 189 8,12 349 14,98 504 21,64 218 9,36 177 7,60 126 5,41 23310,00 97 4,16 232992,53
Germany 93 14,03 60 9,05 114 17,19 170 25,64 38 5,73 62 9,35 44 6,64 50 7,54 32 4,83 66326,34
United Kingdom 117 22,90 30 5,87 60 11,74 87 17,03 53 10,37 34 6,65 25 4,89 8817,22 17 3,33 51120,30
France 82 16,94 41 8,47 85 17,56 107 22,11 61 12,60 36 7,44 30 6,20 24 4,96 18 3,72 48419,23
Sweden 47 26,26 7 3,91 20 11,17 24 13,41 14 7,82 20 11,17 12 6,70 1910,61 16 8,94 179 7,11
Switzerland 25 22,32 5 4,46 11 9,82 17 15,18 11 9,82 4 3,57 7 6,25 2724,11 5 4,46 112 4,45
Italy 24 21,24 16 14,16 13 11,50 18 15,93 16 14,16 8 7,08 3 2,65 1412,39 1 0,88 113 4,49
Others4 16 21,05 4 5,26 13 17,11 19 25,00 8 10,53 4 5,26 5 6,58 5 6,58 2 2,63 76 3,02
Total 477 18,95 198 7,87 373 14,82 540 21,45 237 9,42 185 7,35 138 5,48 26510,53 104 4,13 2517
1 Chemical Synthesis: Includes Combinatorial Chemistry, Chiral Chemistry, Molecular Synthesis    
2 Others Devices: Includes Medical Equipments, PCR    
3 Analysis: Environmental and Agro-Food Test   
4 Others:Czech Republic, Estonia, Hungary, Iceland, Lithuania, Norway, Poland, Portugal, Romania, Russia, Slovakia     
 
41
processes. First-generation process biotechnology (such as fermentation and
bioremediation) appears to be less and less relevant in the characterisation of firms
profiles and core technological capabilities.
Diversification and integration
Tables 4.5 and 4.6 give an account of the extent of diversification of DBFs in
Europe, in terms of fields of application and research technologies. Companies
monitored in the survey were classified according to the characterisation that they
provide of their own business and technological background. In Table 4.5, DBFs that
identify their activity exclusively in terms of technological background are labelled
as ‘basic’ companies. Analogously, DBFs that are characterised only by field of
application, and do not refer to any specific technological background, are classified
as ‘applied’ in Table 4.5. In both cases, DBFs that refer to a given area of
specialisation are labelled as ‘specialised’, while firms with at least two fields of
interest are labelled as ‘diversified’18.
Tables 4.5 and 4.6 show that European DBFs tend to be either technologically
specialised in given fields of application or active in baseline research and
technology development. Almost 50% of European DBFs are specialised in one
specific domain in terms of technological background or field of application.
Notably, a high share of Swedish and German firms are specialised in general-
purpose technologies (GPTs). Italian firms have, on average, the highest degree of
diversification, followed by French DBFs.
                                                
18 Sub categories have been identified according to the number of fields the company operates in: Low (2 fields),
Medium (3) and High (more than 3) levels of diversification are reported.
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Figure 4.7. European DBFs: Cohorts of Entrants by Technological Background 
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Biotechnology; DNA - Genomics and Genetic Engineering; Sub - Subcellular Organisms; Chem - 
Chemical Synthesis (including Combinatorial); Bioinf – Bioinformatics 
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Source: Pammolli and Riccaboni, 2001, based on BID, University of Siena 
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IV. 4   Summary of Main Results
The entry of European DBFs is a recent phenomenon. From 1996 to 2000 the overall
number of EU biotechnology firms almost doubled and the growth has been
particularly strong in Germany. More recently, the rates of company formation have
decreased.
Table 4.5. Diversification Profiles of European DBFs: Areas of Application
 
Source: BID, University of Siena 
Degree of 
Diversification 
  
Germany United Kingdom France Sweden Switzerland Italy EU 15 Other 
  Num. % Num. % Num. % Num. % Num. % Num. % Num. % Num. %
Basic  127 27,08 30 8,17 30 10,56 44 23,78 16 19,28 3 5,08 260 15,86 32 9,76
Specialized  200 42,64 198 53,95 129 45,42 109 58,92 48 57,83 18 30,51 799 48,75 169 51,52
Diversification Low 97 20,68 85 23,16 72 25,35 24 12,97 15 18,07 20 33,90 373 22,76 86 26,22
 Medium 30 6,40 35 9,54 36 12,68 8 4,32 3 3,61 10 16,95 137 8,36 28 8,54
 High 15 3,20 19 5,18 17 5,99 0 0,00 1 1,20 8 13,56 70 4,27 13 3,96
Total  469 100,00 367 100,00 284 100,00 185 100,00 83 100,00 59 100,00 1639 100,00 328 100,00
Table 4.6. Diversification Profiles of European DBFs: Technological Background  
 Source: BID, University of Siena 
Degree of 
Diversification 
  
Germany United Kingdom France Sweden Switzerland Italy EU 15 Other 
  Num. % Num. % Num. % Num. % Num. % Num. %Num. % Num. %
Basic  93 19,83 109 29,70 57 20,07 65 35,14 30 36,14 9 15,25 405 24,71 83 25,30
Specialized  227 48,40 153 41,69 113 39,79 100 54,05 32 38,55 23 38,98 732 44,66 141 42,99
Diversification Low 111 23,67 74 20,16 55 19,37 16 8,65 17 20,48 13 22,03 327 19,95 68 20,73
 Medium 25 5,33 22 5,99 33 11,62 4 2,16 2 2,41 9 15,25 114 6,96 25 7,62
 High 13 2,77 9 2,45 26 9,15 0 0,00 2 2,41 5 8,47 61 3,72 11 3,35
Total  469 100,00 367 100,00 284 100,00 185 100,00 83 100,00 59 100,00 1639 100,00 328 100,00
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European DBFs are typically extremely small, much smaller than their American
equivalents.
Germany leads the league in terms of number of dedicated companies, with more
than 500 small independent dedicated biotechnology firms (DBFs), followed closely
by the UK. Taken together, Germany and the UK account for about one half of the
total number of DBFs in Europe. France ranks third and Sweden follows.
If one calibrates the number of DBFs using population or GDP numbers, a clear
representation emerges, with Sweden ranked first according to both measures,
followed by Switzerland, Ireland, Finland, and Denmark. The UK, Germany and
France have similar values while Italy and Spain have the lowest ratios. In sum, these
data confirm the good performance of the small (Northern European) countries.
The new European DBFs are active mainly in the so-called “platform technologies”,
e.g. genomics, combinatorial chemistry and bio-informatics. The proportion of DBFs
active in the agro-food sector has declined sharply.
European DBFs tend to be specialised either in narrow fields of application or in
baseline research technologies.
French and British companies show the highest degree of integration between
technologies and applications. On the contrary, German and, particularly, a
significant fraction of Swedish firms, tend to be specialised either in terms of
technologies or domains of application.
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V  Geographical Clusters in European Biotechnology
V.1. Introduction
In the US, biotechnology has been characterised, historically, by a relatively high
concentration of firms, employment, and activities in a restricted number of regions,
mainly in the US (San Diego, the Bay Area, Boston, New Jersey, New York
metropolitan area, Maryland (between Baltimore and Washington DC), and the
Houston area in Texas) (see Owen Smith, Riccaboni, Pammolli, Powell, 2001;
Zucker, Darby, 2001).
Based on this, economists, analysts and policy-makers have argued that spatial
concentration of innovative and industrial activities is indeed a  pre-requisite for the
successful development of biotechnology and policies have been devised (e.g. the
German BioRegio Program) with the explicit aim to support not so much the birth of
new DBFs but rather the development of clusters of biotechnology activities.
Why is such concentration observed? As this is fundamentally a science-based
technology, involving abstract and codified knowledge, it should  in principle be
available to everybody. What forces lead to the agglomeration of biotechnology
activities in specific clusters? Different explanations have been suggested:
• the (partially) tacit nature of knowledge implies that personal contacts,
imitation and frequent interactions are necessary for knowledge transmission.
These are clearly possible at lower costs for firms located within the same
city or region. The transmission of tacit knowledge requires mutual trust, a
sharing of language and culture and intense non-business relations that co-
location in areas of homogeneous social background makes easier (Jaffe,
Trajtenberg and Henderson, 1993; Audretsch and Feldman 1996; Swann and
Prevezer, 1998);
•  discoveries in this technological area are characterised by high degrees of
natural excludability, i.e. techniques for their replication are not widely
known and anyone wishing to build on new knowledge must gain access to
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the research team or laboratory setting having that know–how (Zucker, Darby
and Brewer, 1997, Zucker, Darby and Armstrong, 1998; Audretsch, 2001). In
these circumstances, inventor–scientists tend to enter into contractual
arrangements with existing firms or start their own firm in order to extract the
supranormal returns from the fruits of their intellectual contribution. And they
tend to do so within commuting distance from their laboratories19;
•  however, empirical evidence suggests that there might be a threshold effect
(Echeverri-Carroll and Brennan, 1999): local sources of knowledge are key in
determining success in the development of new products and processes only
in areas with a large accumulation of knowledge (Silicon Valley). Innovations
by firms located in other areas depend on distant relationships with
universities, and other high–technology firms (suppliers and customers)
located elsewhere, especially in urban centres. In this perspective, local
boundaries play a fundamental role for the recruitment of skilled workforce
and technical personnel. However, the most dynamic and innovative firms
look for knowledge embodied in engineers and scientists wherever they are
available, and are not necessarily constrained in this by geographical barriers.
Local knowledge sources are relatively less important for firms located in
lower-order regions. For these firms, local universities are viewed as
suppliers of skilled workforce, rather than loci of innovations or sources of
product ideas or spillover effects. In order to sustain high rates of innovation
they must develop linkages with actors (universities and other high-tech
firms) located in higher-order regions (see also Lyons, 1995).
Trying to draw some conclusions from this discussion, it would appear that clustering
may be the outcome of different factors, but mainly:
                                                
19 Zucker, Darby, and colleagues have shown that the innovative performance of biotechnology firms is
positively associated  with the total number of articles by local university ‘star’ scientists. However, when the
number of articles written by university stars is broken down into those written in collaboration with firm
scientists (‘linked’) and the remaining (‘untied’), the coefficient on articles written by local university stars not in
collaboration with the firm loses its significance and nearly vanishes in magnitude. Previous evidence on the
existence of localised knowledge spillovers seems therefore to have resulted from a specification error, i.e. the
inability to control for the actual relationships linking individual scientists to individual firms.
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– the existence of a strong critical mass of scientific knowledge, in absolute terms:
in other words, excellence in scientific research is a basic precondition for
attracting innovative activities. In its absence,  firms (incumbents and/or
prospective entrepreneurs) might look for other locations   to tap the relevant
knowledge. Moreover, diversity is also important. Insofar as innovation rests on
the integration of different fragments of knowledge, the presence of a diversified
scientific base becomes a key issue;
– the existence of a strong and diversified industrial base, with accumulated
capabilities and organisational structures enabling them to actually participate in
the network of cognitive and social relationships that are necessary to get access
to, to absorb, integrate the new knowledge and, on these bases, to engage in
successful innovative activities;
– the existence of specific and often formal organisational devices (including
markets for know-how) that allow flows of knowledge to take place.
V. 2 Regional Distribution of Biotechnology Patents in Europe
Geographical concentration of biotechnology in Europe: Evidence from patent data
Table 5.1 shows the regional distribution of the 4,649 patents invented in Europe
from the sample of 10,000 chemical patents. The table lists the top 20 regions in
which patenting activity in chemicals concentrates among the 146 European regions
as classified by Eurostat at the NUTS1 and NUTS2 level. (See Mariani, 2001, for
further details).
The top 20 regions (13,7% of the total number of regions) account for 77.5% of the
sample of chemical patents invented in Europe. The top 10 regions (6.8% of the
total) host 59.5% of these patents. The distribution of chemical patents across
European regions is highly concentrated.
There are many German regions among the top 20, ranging from 5 in biotechnology
to 9 in pharmaceuticals. This is consistent with the well–known leadership of
Germany in chemicals, although the lower number of German regions among the top
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20 regions in biotechnology confirms earlier remarks about its lower specialisation in
this field. Other studies show that, in general, many of the most innovative European
regions are in Germany (Paci and Usai, 1998). Overall, 52% of the patents invented
in the top 20 regions were invented in Germany. Germany is followed by France
(with 13.8% of the patents in the top 20 regions), the UK (13.8%), the Netherlands
(5.3%) and Italy (4.6%).
Although the data in Table 5.1 show that patenting concentrates geographically in all
five chemical branches, biotechnology shows the least geographic concentration. In
the sample, the top 20 regions account for 68.6% of the biotechnology patents
invented in Europe. There are some regions that appear in all five listings in the top
20 positions. These are South–East England, Île de France, Bayern, Hessen, West-
Netherland, Nordrhein-Westfalen, Baden-Württemberg, Vlaams Gewest and Rhône-
Alpes. There are other regions, such as Rheinland-Pfalz and Sachsen, which are in
the top 20 positions in all the chemical sectors, except in biotechnology.
There are also regions that are ranked in the top 20 positions in biotechnology, but
that are not among the top 20 in any of the other four chemical fields. This suggests a
peculiarity of biotechnology within the overall chemical sector, especially that
biotechnology is a technology that facilitates the entry of new actors. Specifically, it
is opening up opportunities for regions that have not been active in developing
innovations in the traditional branches of the chemical sector, including
pharmaceuticals. The new regions in the top 20 for biotechnology are Københavns in
Denmark, Uusimaa in Finland, Stockholm in Sweden, and the area around Madrid in
Spain. This suggests that biotechnology offers opportunities for new entries in
technologically dynamic fields.
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Table 5.1: Distribution of patents across European regions (region of the inventor): cumulative frequencies and Herfindahl index.
top 20 regions (10 000 patent sample in 1987-1996)
Biotechnology Materials Organic chemicals Pharmaceuticals Polymers
Regions Cum.Freq. Regions
Cum.
Freq. Regions
Cum.
Freq. Regions
Cum.
Freq. Regions
Cum.
Freq.
South East Engl. (UK) 8,6 Nordrhein-Westfalen (DE) 14,3 Nordrhein-Westfalen (DE) 15,3 Nordrhein-Westfalen (DE) 12,9 Nordrhein-Westfalen (DE) 20,8
Île de France (FR) 15,9 Hessen (DE) 22,3 Hessen (DE) 24,9 Île de France (FR) 23,7 Rheinland-Pfalz (DE) 33,9
Bayern (DE) 21,5 Île de France (FR) 29,0 Rheinland-Pfalz (DE) 34,4 South East Engl. (UK) 31,5 Hessen (DE) 40,5
Hessen (DE) 26,9 Rheinland-Pfalz (DE) 34,4 Switzerland 42,2 Hessen (DE) 37,0 Switzerland 44,2
West-Nederland (NL) 31,5 West-Nederland (NL) 39,3 South East Engl. (UK) 49,5 North West Eng. (UK) 41,7 Rhône-Alpes (FR) 47,9
Switzerland 35,6 North West Eng. (UK) 43,8 Île de France (FR) 55,7 Switzerland 46,2 Lombardia (IT) 51,5
Eastern (UK) 39,5 Vlaams Gewest (BE) 47,8 Lombardia (IT) 59,8 Lombardia (IT) 50,5 Île de France (FR) 54,8
Nordrhein-Westfalen (DE) 42,9 Baden-Württemberg (DE) 51,8 Sachsen-Anhalt (DE) 62,6 Rheinland-Pfalz (DE) 54,6 Sachsen (DE) 57,6
Københavns amt (DK) 46,2 Sachsen (DE) 55,4 Rhône-Alpes (FR) 65,5 West-Nederland (NL) 57,7 West-Nederland (NL) 60,4
Baden-Württemberg (DE) 49,2 Zuid-Nederland (NL) 58,5 Sachsen (DE) 68,2 Baden-Württemberg (DE) 60,4 Zuid-Nederland (NL) 62,9
Niedersachsen (DE) 52,0 North East Eng. (UK) 61,6 Baden-Württemberg (DE) 70,9 Sachsen-Anhalt (DE) 62,7 Sachsen-Anhalt (DE) 65,4
Vlaams Gewest (BE) 54,5 Bayern (DE) 64,3 Bayern (DE) 73,0 Bayern (DE) 65,1 North West Eng. (UK) 67,9
Ostösterreich (AT) 56,6 Niedersachsen (DE) 67,0 West-Nederland (NL) 75,1 Berlin (DE) 67,3 Vlaams Gewest (BE) 70,1
Rhône-Alpes (FR) 58,6 Sachsen-Anhalt (DE) 69,2 Vlaams Gewest (BE) 77,2 Vlaams Gewest (BE) 69,3 Bayern (DE) 72,3
Berlin (DE) 60,4 Rhône-Alpes (FR) 71,4 Sachsen (DE) 78,7 Eastern (UK) 71,2 Région Wallonne (BE) 74,4
Lombardia (IT) 62,2 South East Engl. (UK) 73,7 Alsace (FR) 80,2 Lazio (IT) 73,0 Emilia-Romagna (IT) 76,4
Alsace (FR) 63,8 Ostösterreich (AT) 75,0 Eastern Eng. (UK) 81,5 FR71 Rhône-Alpes 74,7 Baden-Württemberg (DE) 78,3
Uusimaa (FI) 65,5 Bruxelles (BE) 76,3 Berlin (DE) 82,9 Hamburg (DE) 75,9 South East Engl. (UK) 80,1
Stockholm (SE) 67,1 Région Wallonne (BE) 77,7 Scotland (UK) 83,9 North East Eng. (UK) 77,1 Niedersachsen (DE) 81,5
Comunidad de Madrid (ES) 68,6 Haute-Normandie (FR) 79,0 Cataluña (ES) 84,7 Sachsen (DE) 78,2 Bruxelles (BE) 82,9
Herfindahl index 0,03 0,05 0,07 0,05 0,08
Source: Mariani, 2001.
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Clusters of biotechnology activities in Europe
In this section, which is an extract from Pammolli and Riccaboni, 2001, the main
biotechnology clusters in Europe are identified, by looking directly at firms and
research centres, based on BID.  Figures 5.1 to 5.5 show that a process of clustering
is taking place in Europe where a relatively small number of local clusters are
capturing a dominant majority of biotechnology firms and of public research
organisations.  Some of these clusters (i.e. Oxford, Cambridge, and Stockholm) are
more consolidated and can rely upon a sound research background and high
international reputation, coupled with a critical mass of both young and established
spin-off companies and international contacts. Other biotechnology clusters, like the
German Bio-Regions (Munich, Rhine/Neckar and Rhineland), some French districts
and, to a lesser extent, the Medicon Valley between Copenhagen and Lund, are
younger. They they took off during the Nineties mainly thanks to a supportive policy
environment, availability of public and private finance, new infrastructures, the
presence of large companies active in related industries and institutes of research in
biomolecular biology, biomedical sciences and biochemistry. Biotechnology
activities in Germany, UK, France, Sweden, and Switzerland (Figure 5.1a) are
concentrated in a handful of clusters (Figure 5.1b).
Figure 5.1 (a). European Dedicated Biotechnology Firms: Employment by
Country
Source: BID, University of Siena
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Apparently, most of the factors that contribute to the growth of the  national systems
of biotechnology innovation and production are local in nature. Figures 5.2 to 5.5
provide a descriptive atlas of biotechnology regions in Europe.
In the UK, British DBFs are clustered in East Anglia (Cambridge),  South East
England (Oxfordshire, Great London, Surrey), and Central Scotland (see Figure 5.2;
see also DTI, 1999 and 2001). A circle of 10 kilometres includes most of the
activities around the Oxford and Cambridge campuses, as well as within the City of
London. Each of these regions encompasses  a variegated set of public and private
research organisations. In addition to the university, Oxford includes other
prestigious research organisations and hospitals (John Radcliffe Hospital, AEA
Technology, MRC Radiobiology Institute, and Wellcome Trust Human Genetics
Center). Also, a number of well-known Oxford spin–offs are located along the A34
corridor from Oxford to Didcot (i.e. Oxford GlycoSciences, Oxford Asymmetry,
Powderject Pharmaceuticals). Around the University Campus in Cambridge, one can
find other leading institutes (Laboratory of Molecular Biology, the Babraham
Institute, the Sanger Centre, and the European Bioinformatics Institute), as well as
27% of UK DBFs, with a vast variety of technological and business profiles. Finally,
a large variety of actors – public research organisations (Imperial College, Medical
Research Council, University College), research hospitals (Guy’s and St Thomas’
Hospital), venture capitalists, headquarters of the main pharmaceutical and chemical
enterprises and new biotechnology firms – are located in London.
Most of the firms active in the London area are active in biopharmaceuticals, with
particular reference to decoding/transformation of DNA material or functions of sub-
cellular organisms.
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Figure 5.1 (b). European Dedicated Biotechnology Firms:
Main Geographical Clusters
Source: BID, University of Siena
Companies specialised in functional genomics, the production of vaccines and
biomaterials, and drug delivery systems are also located in London. In the East
Anglia Cluster (Cambridgeshire), biopharmaceuticals are by far the most important
segment, with a variety of profiles, ranging from large first generation biotechnology
companies, to drug discovery companies specialised in the fields of genomics,
proteomics, bioinformatics, combinatorial chemistry, to firms specialised in the
development of techniques of protein/rDNA sequencing/engineering and, finally, to
firms specialised in the production of biomaterials. In Surrey one can observe a
higher proportion of firms active in agricultural biotechnology and, moreover, in the
production of reagents and of cell and tissue cultures. On the contrary, in Oxfordshire
almost all DBFs tend to be specialised in biopharmaceuticals, with particular
reference to proteomics, genomics, the development of chemical libraries, and the
production of vaccines and monoclonal antibodies. Finally, 25-30 DBFs are located
in Scotland, with competencies in human and animal healthcare, as well as in
environmental biotechnology, covering technological fields such as gene therapy,
protein engineering, and combinatorial chemistry.
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Figure 5.2. Main UK Biotechnology Clusters
Source: BID, University of Siena
On 20 November 1996, the German Federal Ministry for Education, Science,
Research and Technology announced the three winners of the BioRegio competition
(see Dohse, 2000). Munich, Rhine/Neckar and Rhineland received an extra DM 50
million of federal funding over the next five years and at least the same amount from
industry. Also as a consequence of this program, German DBFs tend to be localised
in Bayern, Baden-Württenberg, Rheinland-Pfalz, Nordrhein-Westfalen, and Berlin
(see Figure 5.3). Many of the new DBFs benefited from the BioRegio program and
located their activities close to leading institutes of research. As an example, Figure
5.3 focuses on the Munich and Freiburg clusters and reveals the presence of a high
number of early-stage platform biotechnology companies closely connected to local
PROs. All these clusters emerged in the last 5 years, thanks to both strong public and
private support and world–class local research institutes, particularly in small
molecule discovery and computational chemistry.
In the Berlin area, one can observe a high number of diagnostic firms and, moreover,
DBFs specialised in the fields of genomics and proteomics. Freiburg (Baden-
Württemberg) is characterised by a remarkable degree of technological diversity,
both in biopharmaceuticals and agricultural biotechnology. The cluster around
Hamburg is populated mainly by DBFs specialised in the analysis of nucleic acid, in
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the production of in vitro diagnostics and in drug discovery, with particular reference
to the development of target molecules or target genes for specific diseases, while the
platform technologies of genomics and proteomics are diffused among DBFs located
in Bayern (Munich, Martinsried), where one can find also firms specialised in the
provision of software tools and know-how for bioinformatics and functional
genomics.
Figure 5.3. German Biotechnology Clusters: Bayern and Baden-Württenberg
Source: BID, University of Siena
Figure 5.4 shows the high concentration of French biotechnology firms in Paris, the
second largest cluster in terms of number of DBFs in Europe after Cambridge
(Mytehlka, Pellegrin, 2001). According to BID data, about 30% of French
biotechnology firms are located in Paris trailed by a group of French regions
(Auvergne, Loire, Rhone-Alpes and Midi Pyrennees) that have been catching up in
the last five years (see France Biotech, 2000). Here again, in a 10 km2 area one can
find a heterogeneous set of both public and private biotechnology organisations.
More than 100 DBFs are located around Paris, many specialising  in diagnostics and
therapeutics (genetic engineering, cell and tissue culture). In Alsace, out of 36
companies monitored in BID, 12 are active in agro-food, 5 in environmental
biotechnology, and 19 in biopharmaceuticals, with particular strengths in  proteomics
and gene delivery technologies. Agro-food is important also in the Rhone-Alpes area,
55
with relatively large DBFs using both traditional fermentation techniques and more
innovative techniques derived from genomics and proteomics.
Figure 5.4. French Biotechnology Companies: Île-de-France
Source: BID, University of Siena
Figure 5.5 shows two large Nordic clusters. The Novum Biopark in Stockholm is
closely related to the Karolinska Institute Complex, which has a long tradition of
excellence in medical and biological fields. The southern region (Øresund), is known
as Medicon Valley (Horton, 1999). Medicon Valley has grown up between
Copenhagen and Lund–Malmö, especially after the construction of the bridge
between Denmark and Sweden. Almost all biotechnology firms in Sweden are
located in four major regions: Stockholm-Uppsala, Skåne, which is the southern
region including Lund and Malmö, Gothenburg and Umeå (Vinnova, 2000), while in
Denmark they are highly concentrated in the Sjælland Island. The Stockholm area is
populated by DBFs active in biopharmaceuticals, with a focus on vaccine research
and production and the technologies of cell-therapy, proteomics, and genomics. The
region around Uppsala is populated by DBFs specialised in biopharmaceuticals
(mainly in cell culture), while the Sydsverige cluster is more differentiated.
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Figure 5.5. Main Nordic Biotechnology Clusters
Source: BID,
University of Siena
Other fast-growing clusters are in Finland (Helsinki, Turku, Tampere, Kuopio, Oulu)20,
in the Netherlands (Zuid-Holland Region), and in Lombardia (Milan).
This data review suggests two remarks. First, clustering would seem to be strongly
related to the presence of heterogeneous and interconnected prestigious research
institutions. And, second, the main clusters are not simply characterised by dense
internal or local relations but also by the ability to establish strong and varied external
ties with other clusters.
European clusters such as Cambridge, Oxford and Karolinska show a remarkable degree
of organisational heterogeneity and internal interconnectivity, comparable to the one
characterising the most important clusters in the US. The Swedish collaborative network
                                                
20 The main Finnish biotechnology centers are located in the Helsinki Metropolitan Area (Uusimaa) and in the
Etelae-Suomi region (mainly in Turku and Tampere) (see Kuusi, 2001). Local relationship with public research
organizations appear to be crucial for the success of there regions. Finland ranks first in Europe in terms of
proportion of innovative firms having cooperative agreements with universities. More than a half of Finnish high-
tech companies collaborate with universities vs. a European mean of only 12% (Eurostat, 2000), and these
contacts are particularly intense in life sciences. The Helsinki Science Park and Biomedicum are initiatives
designedt around top-level Finnish research institutes in Helsinki: the University of Helsinki, the Viikki
Biocentre, the National Public Health Institute and the Helsinki University of Technology. Other important
centres of expertise are located in Tampere and Turku.
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presented in Figure 5.6 shows the central role of the Karolinska complex (Karolinska
Institute and KaroBio) in the middle between the Astra and Pharmacia stars of
international contacts. The most important cluster of Swedish biotechnology firms
around Karolinska is brought into closer connection by diverse organisations located
outside Sweden. As in the case of the most important US clusters (see Owen-Smith,
Riccaboni, Pammolli, Powell, 2001), the density of the Swedish national innovation
network is greatly increased by the inclusion of diverse organisations from other
geographic locations. Moreover, the Swedish picture emphasises the central role that
small science–based firms can play in reaching out to other areas.
This model suggests that successful systems of innovation in biotechnology appear to
grow from “old” regional clusters, developed around the strength of scientific
expertise, the integrative capabilities of established pharmaceutical companies, and
the dynamic role of small firms. These clusters have become over time both
internally denser and much more outward–oriented.
In the second model of EU clusters (many French and German regions) networking
is not yet developed to the same extent. . They seem to lack interdisciplinary teams
and the connections across stages of the R&D process that dense webs of local
relations among hospitals, university labs, and firms make possible. These
difficulties, together with the centralisation and bureaucratisation of some of the
relevant evaluation and selection processes, could constitute an inherent element of
fragility for some of the younger clusters in continental Europe.
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Figure 5.6. The Swedish Network of R&D Collaborations in Biopharmaceuticals
Source: BID, University of Siena
Legend:
Shape: Nationality Colour: Organization Type Size: Critical points for network connectivity
Circles – Swedish organizations White – New Biotechnology Firms Large nodes – Articulation points
Boxes – US partners Gray – Public Research Organizations Small nodes – Peripheral nodes
Diamonds – European partners Black – Large Established Companies
Triangles – Other partners
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These result would seem to lend some support to the notion that biotechnology is indeed
characterised by a strong tendency towards clustering and that it derives to a large extent
from  the availability of a strong, heterogeneous but integrated research base that
facilitates the transfer and the integration of knowledge, as well as the development of
skilled labour, the mobility of such labour and – presumably – also the development of
other supporting institutions like venture capital.
However, the tendency towards clustering is accompanied by a parallel process of
increasing openness of the original clusters, a process also noted in the US. Recent
trends suggest a combination of an increasing number of collaborations and a decreasing
proportion of local connections. In the USA too, local ties moved from a high of 40% in
1988 to a low of 8% in 1998 (Owen-Smith, Riccaboni, Pammolli, Powell, 2001), in the
context of a rising volume of collaborations (the number of ties active in 1998  was more
than double the number a decade before).
In general, the recent evolution of the biotechnology industry has sustained a
combination of an increasing number of collaborations and a decreasing proportion of
local connections. This tendency might derive from different factors. One of the most
likely resides in the need to get access to state-of-the art knowledge, wherever it might
be located. Sustained performances are based on leading-edge research, which cannot be
exclusively local. Second, the tendency towards clustering and subsequent de-
localisation might also derive from the very properties of the evolution of knowledge in
biotechnology (Orsenigo, Pammolli, Riccaboni, 2001), in relation to the diffusion of
“platform”, general purpose technologies (see also Pammolli and Riccaboni, 2001).
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VI. Institutional Factors that Affect Industrial Competitiveness in Biotechnology
VI. I. Introduction
The commercial development of European biotechnology, as already indicated
previously, is lagging significantly behind the USA. Despite encouraging signals of
dynamism – especially  from the small Northern European countries – and a wave of
entry of new DBFs – especially in Germany – innovative activities remain far below
US levels. European companies  make significant use of  American research while
US firms do not seem to  make as much use of the European research. The new
European DBFs are much smaller than their American counterparts, much less active
in the global network of collaborative relations and in the markets for technology,
and mainly present in platform technologies.
One explanation for this may be that US firms enjoy first–mover advantages. In
technologies where innovative activities are often characterised by increasing returns,
first–mover advantages are an important phenomenon and are likely to provide long–
lasting and difficult to erode leadership. European DBFs may have simply been pre-
empted by their American counterparts, while the excellence of the American
scientific research system has attracted financial and human resources from all parts
of the world, further strengthening US leadership in biotechnology. However, other
variables have likely played a role. With biotechnology being fundamentally science–
based, and characterised by rapid innovation, it is possible that, at least partially,
first–mover advantages may not be sustainable. Under these circumstances, catching–
up and forging ahead – at the firm and country level – might be possible.
This section reviews some major institutional determinants of industrial
competitiveness in biotechnology that might have hindered its development in
Europe.
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VI.2 The Structure of the Research System
Funding
Biomedical research is expensive and public money always played an important role
in supporting this field. With the takeoff of biotechnology the cost of research
increased further, thus making a strong support even more necessary in maintaining
high-quality competitive research.
Molecular biology was developed predominantly in the USA and in the UK even
though significant research groups were active in many other European countries
(Morange, 1998). After World War II, US support for research in life sciences
literally exploded. Public funding of biomedical research in the post–war period
increased dramatically in Europe too, but total spending remained significantly lower
than in the USA. The sheer size of resources devoted to biomedical research in the
US in the post–war era explains much of the American leadership in life sciences.
In the US, the funding of biomedical research has been designed around the National
Institutes of Health (Stokes, 1997). In 1998 the budget for funding extramural
research was of $ 8 billion. Biomedical research is expensive and public money
always played an important role in supporting this field. With the advent of
biotechnology the cost of research increased further, thus making a strong support
even more necessary in maintaining high-quality competitive research.
As a contrast, the total budget of the 5th Framework Programme (1998-2002) is about
€ 15 billion21. The first prevision for the total budget of the 6th Framework
Programme (2002-2006) is of € 17.5 billion, equal to the NIH budget for the year
2003 at current exchange rates.
Table 6.1 provides an indication on the relative importance of public funding for
biotechnology in different OECD member countries other than the US. In absolute
PPP$ terms Germany spends the most on biotechnology, followed by the United
Kingdom and France. The median contribution of government budgets dedicated to
biotechnology is 3.5%, with a quite large spread, ranging from 0.4% in Italy to
13.8% in Belgium, 10.1% in Canada,  and 8.1% in Finland.
                                                
21 In addition, the Quality of Life Programme budget, only partially devoted to biotechnology, is € 2.4 billion.
62
Table 6.1: Public funding of Research and Development in biotechnology (1997)
Biotechnology R&D
Total Government Budget
Appropriations or
Outlays for R&D
(GBOARD)
R&D Biotech/R&D
Overall
Millions PPP$ Percent
Austria 16.8 1.146.5 1.5%
Belgium 181.7 1.314.0 13.8%
Canada 261.4 2.581.0 10.1%
Denmark 45.2 945.6 4.8%
Finland 94.5 1.165.0 8.1%
France 560.0 12.683.1 4.4%
Germany 1.048.2 15.595.7 6.7%
Greece 6.5 430.9 1.5%
Iceland 0.9 68.5 1.3%
Ireland 15.0 229.9 6.5%
Italy 32.1 7.329.6 0.4%
Netherlands 78.0 3.069.9 2.5%
Norway1 26.8 - 32.2 880.3 3%-3.7%
Portugal 19.2 781.9 2.5%
Spain 15.5 3.202.6 0.5%
Sweden2 65.6 1.795.2 3.7%
Switzerland2 16.4 1.379.7 1.2%
United Kingdom 705.1 9.055.7 7.8%
Remarks:
1. These data are national estimates, hence the range.
2. GBOARD has been estimated.
Source: OECD, based on data from the European Commission (Inventory of public biotechnology
R&D programmes in Europe, 2000), Eurostat, Statistics Canada, and national sources.
The institutional structure of research
The institutional structure of biomedical evolved quite differently in continental
Europe as opposed to the USA (and partly to the UK).
There is substantial integration between the production of biological knowledge
concerning the nature and mechanisms of human diseases, clinical research, medical
practice, and the discovery and development of new therapeutic treatments; and
significant support for fundamental science in universities and public research
centres, widely disseminated through publication in the refereed literature. Moreover,
the US system is characterised by a variety of sources of funding and selection
mechanisms, which complement the role of the NIH and act according to different
allocative principles (see Stokes, 1997; Braun, 1994; Owen-Smith, Riccaboni,
Pammolli, Powell, 2001). Overall, the US research system achieves efficiency
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through competition among research units providing room, at the same time, for
diversity and institutional flexibility.
In Europe, funding has tended to be administered mainly at the national level, with
strongly differentiated approaches and wide differences across countries. In many
cases, resources have either been spread among a large number of “small”
laboratories, or they have been excessively concentrated in the few available centres
of excellence. Funding coming from the various European programmes has only
partially changed the situation. However, recently the EU Commission has
introduced the new European Research Area concept, proposing huge multicentric
projects for the next 6th Framework Programme, such as Integrated Projects, Centres
of Excellence, and a Clinical Trial Platform.
At present, the absolute size and the higher degree of integration of the American
research system, as opposed to the fragmented collection of national systems in
Europe, constitutes a fundamental difference.  Moreover, one claim of the Report is
that there is a structural alignment between the features of the US biomedical
research system and the intrinsic features of the biotechnology scientific and
technological paradigm, or search regime. The structural coupling between
competition at all levels of the system and variety of institutions involved in research
satisfies the intrinsic tension between the need to explore a large number of
alternative hypotheses and the need to integrate heterogeneous stages of the
exploration and development process.
The organisation and structure of universities
The US research system in the life sciences is highly decentralised. Even public
universities rely on diverse funding sources, including state and national
governments, foundations and corporate supporters, tuition revenues, and alumni
gifts. Private universities, especially elite ones, are also supported by generous
endowments.
The organization of research and teaching has characteristics that facilitate the
flexibility and decentralisation, but also the integration, of research. In the US and
the UK, academic departments have long been the main organisational entities while
in Europe a single professor dominates. The departmental structure makes it easier to
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respond to the emergence of new disciplines, like computer sciences and
biotechnology, both by integrating them in curricula in conventional programs and/or
by creating new departments and programs.
Thus, blurring boundaries between basic and goal-oriented research and increased
competition for research support and funding enable greater mixing of disciplines in
the US (Galambos and Sturchio, 1998; Morange, 1998). Elite research institutes in
the US, such as Cold Spring Harbor, Salk, or Scripps, routinely bring together faculty
from multiple disciplines.
It is possible to argue that, the European model is characterised a high degrees of
division of labour and specialisation between teaching and research institutions,
whereas in the US the dominant model of post-graduate students being exposed and
trained to scientific research within teams composed by students and professors
within departments has been a more integrated one. In Europe, this separation might
have had negative effects on both the quality of research and on the ability of
academic institutions to interact with industry.
Despite national distinguishing characteristics, the structure of research systems in
Europe is profoundly different from the Anglo–Saxon model.
First, in Europe financing is considerably more centralised and, consequently, it
entails more hierarchical control.
Second, research institutions are far less interdisciplinary and flexible. In Germany,
for example, a number of the highly prestigious Max Planck institutes are organised
hierarchically around a single field, such as biochemistry, genetics, or immunology.
Third, the integration of teaching with research has progressed far less than in the US
(and to some extent than in the UK). Ph.Ds are a relatively recent innovation in many
continental European countries and they remain far less professionally orientated
than in the US. Thus, for example, the diffusion of molecular biology into the general
training in many European countries is a relatively recent phenomenon as compared
to the USA and it has become only recently a standard part of the curricula of
pharmacologists, pathologists, medical consultants, and plant biologists.
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Diversity and integration among publicly funded research organisations (PROs)22
The research systems in the US and Europe are organized in qualitatively different
ways; hence any comparison must be sensitive to variation on multiple dimensions.
The analysis is based on 8,031 patents for therapeutically useful compounds or
processes issued by major world patent offices (US, UK, Germany, France, Japan,
European, and the Patent Cooperation Treaty legal office), and assigned to the 98
most prolific non-industrial research organisations, worldwide23.
Figure 6.1 examines the upstream collaborative network among individual PROs to
analyse relationships among organizations. Figure 6.1 is based on patent co-
assignment networks among public research organizations. Each node is a university,
research institute or hospital, and each tie represents two or more patent co-
assignments between the organisations. Several features stand out in this image.
                                                
22 This section is an extract from Owen Smith, Riccaboni, Pammolli and Powell, 2001.
23 These 98 institutions represent more than 70% of all non-industrial patents in this sample. Thus, there is a
natural cut-off point at 98, as the remainder of the distribution is very widely dispersed across hundreds of
organisations. Information on the patents is found in Patent Fast Alert, published by Current Drugs, Ltd.,
London, U.K.
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Figure 6.1. Organization Level Patent Co-Assignment Network for PROs, 1990-99
Source: Owen Smith, Riccaboni, Pammolli, Powell,2001
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B E T M  B e t h  I s r a e l  M e d i c a l  C e n t e r  ( M A )  M P  M a x  P l a n c k  I n s t i t u t  ( G e r m a n y )  
B W  B r i g h a m  a n d  W o m e n ' s  H o s p i t a l  ( M A )  M R C  M e d i c a l  R e s e a r c h  C o u n c i l  ( U K )  
C E D S  C e d a r s - S i n a i  M e d i c a l  C e n t e r  ( C A )  M S I N  M o u n t  S i n a i  H o s p i t a l  ( C a n a d a )  
C H  C h i l d r e n ' s  H o s p i t a l  M e d i c a l  C e n t e r  ( M A )  N C U  U n i v e r s i t y  o f  N o r t h  C a r o l i n a  ( N C )  
C N R S  C e n t r e  N a t .  d e  l a  R e c h e r c h e  S c .  ( F r a n c e )  N I H  N a t i o n a l  I n s t i t u t e s  o f  H e a l t h  ( M D )  
C O L  C o l u m b i a  U n i v e r s i t y  ( N Y )  N Y U  N e w  Y o r k  U n i v e r s i t y  ( N Y )  
C O M M  C o m m o n w e a l t h  S c .  a n d  I n d .  R e s .  O r g .  ( A u s t r a l i a )  O R E G  U n i v e r s i t y  o f  O r e g o n  ( O R )  
C O R N  C o r n e l l  R e s e a r c h  F o u n d a t i o n  ( N Y )  P E N N  U n i v e r s i t y  o f  P e n n s y l v a n i a  ( P A )  
C S H  C o l d  S p r i n g  H a r b o r  L a b .  ( N Y )  P I T T  U n i v e r s i t y  o f  P i t t s b u r g h  ( P A )  
D F  D a n a - F a r b e r  C a n c e r  I n s t i t u t e  ( M A )  P U R  P u r d u e  U n i v e r s i t y  ( I N )  
D K  G e r m a n  C a n c e r  I n s t i t u t e  ( G e r m a n y )  S C R  S c r i p p s  R e s e a r c h  I n s t i t u t e  ( C A )  
D U K E  D u k e  U n i v e r s i t y  ( N C )  S F L U  U n i v e r s i t y  o f  S o u t h  F l o r i d a  ( F L )  
E M O R Y  E m o r y  U n i v e r s i t y  ( G A )  S K  S l o a n  K e t t e r i n g  ( N Y )  
F H  F r e d  H u t c h i n s o n  C a n c e r  R e s .  C e n t e r  ( W A )  S T A N  S t a n f o r d  U n i v e r s i t y  ( C A )  
F L U  U n i v e r s i t y  o f  F l o r i d a  ( F L )  T E M P L E  T e m p l e  U n i v e r s i t y  ( P A )  
G S U  G e o r g i a  S t a t e  U n i v e r s i t y  ( G A )  T E X  U n i v e r s i t y  o f  T e x a s  S y s t e m  ( T X )  
H A R V  H a r v a r d  U n i v e r s i t y  ( M A )  T J E F F  T h o m a s  J e f f e r s o n  U n i v e r s i t y  ( P A )  
I C  I m p e r i a l  C a n c e r  R e s e a r c h  F u n d .  ( U K )  T U L  T u l a n e  U n i v e r s i t y  ( L A )  
I L  U n i v e r s i t y  o f  I l l i n o i s  ( I L )  U A B  U n i v e r s i t y  o f  A l a b a m a  ( A L )  
I N S E R M  I n s t i t u t  N a t i o n a l  d e  l a  S a n t é  e t  d e  l a  R e c h .  M é d i c a l e  ( F r a n c e )  U C  U n i v e r s i t y  o f  C a l i f o r n i a  S y s t e m  ( C A )  
I O W A  U n i v e r s i t y  o f  I o w a  ( I A )  U T A H  U n i v e r s i t y  o f  U t a h  ( U T )  
I P  I n s t i t u t  P a s t e u r  ( F r a n c e )  U W A  U n i v e r s i t y  o f  W a s h i n g t o n  ( W A )  
J H  J o h n s  H o p k i n s  U n i v e r s i t y  ( M D )  W A  W a s h i n g t o n  U n i v e r s i t y  ( M O )  
L U D C  L u d w i g  I n s t .  f o r  C a n c e r  R e s .  ( S w i t z e r l a n d )  W A U  W i s c o n s i n  A l u m n i  R e s e a r c h  F o u n d .  ( W I )  
M E L  U n i v e r s i t y  o f  M e l b o u r n e  ( A u s t r a l i a )  W I  W i s t a r  I n s t i t u t e  ( P A )  
M G H  M a s s a c h u s e t t s  G e n e r a l  H o s p i t a l  ( M A )  Y U  Y a l e  U n i v e r s i t y  ( C T )  
M I C H  U n i v e r s i t y  o f  M i c h i g a n  ( M I )    
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The tightly clustered French, German and British research organizations on the left
side of the figure and the densely connected US regions in the image’s upper right
hand quadrant are the result of minimum-energy network drawing techniques and not
of arbitrary placement.  In addition to demonstrating the coherence of national and
regional R&D systems, close inspection of the patterns of patent co-assignment help
explain the causes of the US leadership in division of innovative labour in
biopharmaceuticals. Note the organizational homogeneity of the French and German
national clusters, which do not include hospitals and have no identified universities24.
The United Kingdom has a somewhat higher degree of organizational diversity,
reflected by the presence of both government and non-profit research and funding
agencies.  Contrast these relatively isolated and homogeneous national clusters with
the large and densely interconnected Boston region in the upper quadrant of the
figure, which is composed of tight, repeated interconnections among a diverse set of
PROs. Elite universities (Harvard, MIT), research institutes (the Dana-Farber Cancer
Center), and hospitals (Brigham and Women’s and Massachusetts General) play
central roles in innovative collaborations both within Boston and across US regions.
Closely-knit regional networks such as those found in Boston help account for the
global centrality of American PROs. But connections across US regions (note for
instance the ties between Harvard, Stanford, and the UC system, connections from
Dana Farber to the University of Chicago, and from Brigham and Women’s hospital
to Duke University) and co-assignment ties linking geographically dispersed
universities to the National Institutes of Health illustrate a public research system that
also reaches across regions and organizational forms. These systemic cross-national
variations in the organization of early-stage research collaborations can explain
national differences in biomedical commercialisation above and beyond variations in
policies or later-stage technology transfer infrastructures.
Relatedly, additional empirical evidence produced by Owen Smith, Riccaboni,
Pammolli, Powell, 2001, show the existence of substantial differences between
leading US and European research institutions in terms of scientific specialisation. In
other words, national specialisation in Europe falls along scientific lines. Points of
                                                
24 Scientists at the CNRS or Max Plancks may well have university laboratories, but the government institute is
identified as their primary affiliation on the patents.
68
excellence develop in both the US and European systems, but in continental Europe
those clusters tend to be limited to narrower specialities and specific nations. The US
are characterised by diverse, substantively generalist research organisations
connected both within and across key regional clusters, though the prevalence of
Boston and California-based research organizations in the core suggests the
importance of regional agglomeration (see Owen-Smith, Riccaboni, Pammolli,
Powell, 2001). British institutions, e.g. Cancer Research Campaign (CRC), Medical
Research Council (MRC), and the British Technology Group (BT) are somewhat
broader in focus but still cluster in therapeutic classes largely related to cancer
research. The greater breadth of the British research system, and its higher degree of
diversity compared to France and Germany, may explain the higher centrality of UK
research institutes in international R&D networks.
These differences in the science base seem to be critical, implying that increases in
scale alone will not alter the focus of R&D efforts because organizations typically
engage in local search, and would continue to patent in those areas in which they are
most skilled. In essence, one reason for greater integration across and within US
regions can be found in the scientific overlap among generalist patentees.  Alterations
in the scale of patenting activity without corresponding shifts in this division of
labour will not make the European system resemble its American counterpart.
Instead, mere increases in scale might deepen specialisation and, perhaps, heighten
fragmentation among European national research systems.
University-industry relations
A further set of factors that explain the US advantage relate to the ability and
willingness of the American academic system to interact with the industrial and
commercial world. The key role acquired by scientific knowledge for technological
innovation manifested itself in an unprecedented intensification of both industry–
university ties and in the direct involvement of academic institutions and scientists in
commercial activities. While both phenomena are not new, since the mid-1970s the
drive towards an increasing commercialisation of the results of research accelerated
dramatically, and patenting and licensing activities on the part of universities started
to soar. The number of universities having established Offices for Technology
Management also increased from 25 in 1980 to 200 in 1990. The creation of spin-
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offs became a distinct and crucial phenomenon of the American academic system.
Increasingly, universities were assuming and were asked to assume the role of direct
engines of (local) economic growth.
The emergence of the entrepreneurial university and the specific forms this process
took in the USA depend strongly on some general characteristics of the social,
institutional and legal context of the USA, including the attitudes towards intellectual
property rights and the availability of venture capital. There is high mobility between
academia and the commercial world – and, more generally, there exists an active
labour market for scientists, technicians, and managerial experts – to a much more
developed extent than in Europe. American university professors often participate in
various forms in commercial activities either retaining their academic affiliation or
migrating back and forth between different affiliations. An alliance between
scientific, organisational and entrepreneurial capabilities (together with a favourable
attitude towards the establishment and enforcement of robust intellectual property
rights) constitutes an essential precondition for growth in industry–university
relations. It is possible to argue that high degree of integration between research and
teaching tends to favour further linkages, easier communication and more intense
flows of knowledge and people between academia and the business world.
Conversely, the ties, bureaucracy, and hierarchies of its scientific institutions, both at
the national and the European levels, strongly discourage labour mobility across
academia and industry. As discussed by Soskice (1997) and Zucker, Darby and
Brewer (1997), the organisation of labour and company law in Europe, combined
with the organisational strategies of most large companies and with the structure of
the academic labour market, constrains the development of US–style active labour
markets, and make it harder for companies to “hire and fire” personnel or rapidly cut
non–performing assets. Moreover, though there is often some lateral movement
across firms very early in a person’s career, the vast majority of European employees
build their own careers within one firm and university.
Correspondingly, the structure of decision–making, remuneration, and career paths
within firms and universities differ fundamentally from the US or UK model. Career
paths, especially in universities, tend to be well specified, incremental, and based on
rank hierarchies. This structure works quite well in industries dependent on long–
term investment strategies in relatively stable technologies, characterised by the
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diffusion of deep skills throughout the firm, but it creates fundamental obstacles to
the creation of high–risk technology firms.
To the extent that innovation depends on the flow of knowledge between university
labs, start–up research firms and large firms, joint research projects and strategic
alliances facilitate this exchange of knowledge. Conversely, if the labour market does
not support extensive lateral career mobility across academia and firms, these
network externalities would be difficult to sustain (Soskice, 1997)25.
In continental Europe, university–industry relationships have developed much more
slowly26 and still now – despite considerable progress – the situation remains
unsatisfactory. Integration of research and teaching and collaboration with industry
has been more frequent in the case of engineering schools and in selected disciplines
in particular countries (chemistry in Germany). Differently from the US, where
universities have gradually extended their functions (an integrated model centred on
universities), continental Europe has leaned towards the development of various
types of specialised institutions for technology transfer who act as intermediaries
between research and industry (the institutional specialisation model).
Thus, there have been a large number of initiatives all across Europe aimed at
establishing stronger links between industry and universities and at encouraging a
more entrepreneurial attitude by universities. In practice, policies have been targeted
mainly towards the setting up of specific devices to manage technology transfer, like
science and technology parks or other such agencies, but their performance has so far
been mixed.
A European Paradox?
Despite the presence of centres of absolute excellence, scientific research in Europe
seems to lag behind the US. This could have created a significant drain of human and
                                                
25 There is interesting evidence in this respect that mobility of researchers across different institutional settings
enhances both scientific research and commercial performance, not only in the US but also in European countries
(Gittelman 2000).
26 More detailed information on the modalities and practices characterising industry-science relations in Europe
can be found in the forthcoming report “Benchmarking Industry-Science relations – the role of framework
conditions” cosponsored by the Austrian Federal Ministry of Economy and Labour and the European
Commission.
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financial resources from Europe to the US that contributes to further strengthen the
American advantage.
There is now significant qualitative and quantitative evidence indicating that the
R&D productivity of large firms as well as the rates of formation of new firms are
highly correlated with the strength of universities and other research institutions in
the underlying sciences (Ward and Dranove, 1995; Cockburn and Henderson 1996;
Zucker, Darby and Brewer, 1997; Swann and Prevezer, 1996).
However, there is less agreement about the existence of a direct link between the
strength of the local science base and industrial and commercial performance. For
example, the UK was a leading location for a disproportionate share of the main
research breakthroughs in biotechnology in the second half of 1900s, but much less
so in the industrial application of such discoveries (Cooke, 2001). More generally, it
is widely believed that scientific, but not industrial, research in Europe fares much
better compared to the US – the so-called European paradox. On this view,
competitive advantages cannot be explained by the strength of the local scientific
base since academic science is rapidly published and thus rapidly available across the
world. Differential performance in industrial biotechnology is more likely explained
by different institutional mechanisms favouring the rapid translation of scientific
research into industrial R&D.
The empirical evidence on the existence and relevance of the European paradox is
mixed. However, the formation of university spin–offs and the emergence of
biotechnology clusters seems to depend less on the existence of academic research as
such than on the presence of “star scientists” and cutting edge research (Zucker,
Darby and Brewer 1997). Similarly, there is substantial – albeit largely anecdotal –
evidence suggesting that successful experiences in industry–university ties in Europe
take place in areas where concentration of world class research in different fields of
biotechnology is available (and where the need for explicit supporting policies is, as
a consequence, less severe).
These observations support the notion that the absolute quality and “quantity” of
scientific research and the coupling of scientific and organisational capabilities
constitute essential preconditions for subsequent developments in industry–university
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relations. Indeed, the development of an entrepreneurial function within universities
in the US has not substituted for their traditional functions.
Rather, the entrepreneurial function appears to be strongly complementary to and
integrated with the other functions, primarily teaching. The US experience would
seem to suggest, in this respect, that linkages with industry simply cannot develop
without the constant mediation of teaching, as a stimulator of demand for
relationships and an important source of absorptive capabilities within firms. In
Europe, the presence of intermediary institutions might in some cases have
paradoxically increased the distance between university and industry, introducing an
additional layer in the relationship instead of favouring the development of
organisational and integrative capabilities within firms and within academic
institutions.
VI. 3 Financial Markets and Venture Capital
The availability of venture capital is commonly invoked as a fundamental ingredient
of American leadership in biotechnology. Clearly, venture capital played an
enormous role in fuelling the growth of the new biotechnology firms. Venture capital
is a long–standing institution in the US financial and innovative system. It was
already active in the beginning of the 20th century and emerged as a vibrant industry
with the electronic revolution in the 1960s. On the contrary, in many European
countries, the lack of developed capital markets for technology firms creates
important barriers for prospective venture capitalists.  Here it is worth recalling how
venture capital plays a crucial role of bridging and complementing different
constituents and roles within the system of biotechnological innovation.
Venture capital provides first of all finance to prospective academic entrepreneurs.
Second, venture capital not only provides finance but also and perhaps more
importantly managerial advice, organisational capabilities and “signals” to
prospective investors about the potential of the new company. Contrary to the
conventional stereotype of the American financial institutions, venture capitalists are
characterised by an extremely strong “hands-on” and “long-run” approach towards
the companies they are financing. A significant number of doctorate holders in
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biology end up working in venture capital firms and venture capitalists have to be
part of the same network of conferences, literature, scientists, etc. Thus, venture
capital mixes technology, academia and finance.
Lack of a developed venture capital market has restricted the start–up of
biotechnology firms outside the US. In Europe, and despite various forms of
intervention at the national and even local level aiming at fostering its formation,
venture capital has only very recently began to develop.
Nevertheless, in Europe there have been many other sources of funds (usually
through government programs) available to prospective start–ups. Moreover, survey
results suggest that financial constraints did not constitute the main obstacle to
establishing new biotechnology firms in Europe (Senker, 1998). Although venture
capital played a critical role in the founding of US biotechnology firms,
collaborations between the new firms and the larger established firms provided a
potentially even more important source of capital. This raises the question why
couldn't prospective European start–ups turn to established pharmaceutical firms as a
source of capital? A speculative but plausible answer could be that European
companies tended to collaborate more with US biotechnology rather than European
firms27. Even in the absence of other institutional barriers to entrepreneurial ventures,
start–ups in Europe might have been crowded out by the large number of US–based
firms anxious to trade non–US marketing rights for capital (Henderson, Orsenigo,
Pisano, 1999). Given the number of American DBFs in search of capital, European
firms interested in commercialising biotechnology had alternatives to investing in
local biotechnology firms.
Finally, the slow development of European venture capital for biotechnology could
reflect less inability or unwillingness of European financial institutions to fund new
ventures and more a scarcity of “good” projects on the part of the industry. Partially
supporting this interpretation, it is worth recalling that several initiatives by both
domestic and foreign investors to launch venture capital funds were attempted in
Europe during the 1990s. Many of these funds, if anything, ended up investing in
new biotechnology companies outside Europe. Conversely, foreign venture capital
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firms have funded some of the few experiences of successful European DBFs. Thus,
the delayed development of venture capital in Europe seems to depend less on the
lack of investors and funds than on the limited  supply of promising start–ups.
The role of venture capital markets in sustaining small, young high–tech firms that
do not meet strict creditworthiness institutional criteria for funding new projects
remains crucial in Europe. Recent evidence suggests that European venture capital
markets are increasingly active in supporting small biotechnology companies in their
innovative efforts. Yet, some potential drawbacks still persist at the interface
between public and private financial markets and institutions, which need to be better
co-ordinated for defining coherent incentive schemes for risk–taking innovative
entrepreneurs.
Table 6.2 shows that, during the period of unprecedented expansion of the European
biotechnology industry (1996-2000), venture capitalists did not change their capital
allocation from less research–intensive sectors toward biotechnology.
While total investment rose from about € 6900 million to € 35000 million, most of it
is devoted to traditional sectors (industrial machinery and equipment, fashion, leisure
products) and to expansion and leveraged buyouts. The main recipient of higher
early–stage investment (seed and start–up financing, about 12% more in 1996-2000)
has been the ICT sectors. US data (Science and Engineering Indicators, 2000) for
1996-1998 show that the share of venture capital devoted to US biotechnology was
more than double, ranging from 6.1% to 8.1% as has the share of seed investments
which varied between 3.8% (1996) and 4.6% (1997)28. Moreover, unlike in Europe,
the period 1996-98 was one of stability for the US biotechnology industry and the
proportion of venture capital disbursements to DBFs was far from its historical 1992
peak. As a result, despite recent growth, European DBFs have continued to attract
only ¼ of the global venture capital investments in biotechnology during the last five
years (Ernst & Young, 2001).
                                                                                                                                         
27 Indeed, most NBFs’ strategies emphasized licensing product rights outside the US to foreign partners. Thus to
an even greater extent than many established US pharmaceutical firms, European firms were well positioned as
partners for US NBFs.
28 Original data provided by the Venture Economics Investor Service, Newark, NJ. Since data on US and
European venture capital come from different sources, they are not strictly comparable (for a tentative
comparison see National Science Foundation, 1998).
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The unique exception to this general trend within the EU appears to be Germany.
Germany’s financial support has favoured biotechnology and start-up investments.
France ranks second both in terms of total investment in biotechnology and of its
share in early–stage financing, followed by the UK. French and German venture
capitalists are playing an important role in supporting the rapid growth of their
national systems of innovation in biotechnology. They are likely to start a phase of
selection and buyouts among the vast population of new European biotechnology
firms and to complement public start–up initiatives by providing financing to
selected growing biotechnology companies. But the unbalanced distribution of
venture capital investments toward American early–stage biotechnology companies
could represent a structural weakness in Europe for a considerable length of time.
Table 6.2: European venture capital disbursements,
by sector and financing stage, 1996–2000 (€1000)
1996 1997 1998 1999 2000
By sector
182.355 250.348 346.354 643.838 1.017.185Biotech
2,70 % 2,60 % 2,40 % 2,60 % 2,90 %
1.347.926 2.306.820 4.026.917 6.418.215 10.976.494Hi-Tech
19,60 % 23,90 % 27,80 % 25,60 % 31,40 %
Total 6.878.646 9.654.942 14.460.781 25.115.694 34.985.753
By stage
68.992 85.137 169.271 467.536 819.680Seed
1,0 % 0,9 % 1,2 % 1,9 % 2,3 %
375.430 625.953 1.468.511 2.771.872 5.843.723Start-up
5,5 % 6,5 % 10,2 % 11,0 % 16,7 %
2.712.015 3.375.956 4.334.539 7.432.678 12.986.306Expansion
40,0 % 35,0 % 30,0 % 29,6 % 37,1 %
481.014 733.017 1.078.675 1.186.228 930.092Replacement Capital
7,1 % 7,6 % 7,5 % 4,7 % 2,7 %
3.150.195 4.834.879 7.409.785 13.257.380 14.405.952Buyout
46,4 % 50,1 % 51,2 % 52,8 % 41,2 %
Total 6.787.646 9.654.942 14.460.781 25.115.694 34.985.753
Source: EVCA (2001).
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VI. 4. The Regulation of Intellectual Property Rights in Biotechnology
Introduction
One important factor contributing to the growth of biotechnology in the US has been
the recognition and enforcement of strong intellectual property rights. The
establishment of clearly defined property rights has played an important role in the
explosion of new firms since, by definition, few firms had complementary assets that
enabled them to appropriate returns from the new science in the absence of strong
patent rights. In the early years of biotechnology, considerable confusion surrounded
the conditions under which patents could be obtained. Research in genetic
engineering was on the borderline between basic and applied science, conducted
primarily in universities or otherwise publicly funded, and the degree to which it was
appropriate to patent results of such research became almost immediately the subject
of controversy29.
IPRs in European biotechnology
By adopting Directive 98/44/EC of the European Parliament and Council on the
Legal Protection of Biotechnology Inventions30, after intensive and lengthy
discussions, the EU equipped itself with a common set of principles regarding the
granting of biotechnology patents. However, in spite of this political commitment,
only four of the fifteen Member States have adopted the necessary legislation.
Most European national legislation did not explicitly address some of the most
controversial problems in the regulation of IPRs in biotech. The dominant situation
                                                
29 Millstein and Kohler's groundbreaking discovery -- hybridoma technology -- was never patented, while
Stanford University filed a patent for Boyer and Cohen's process in 1974. Boyer and Cohen renounced their own
rights to the patent but nevertheless were strongly criticized for having being instrumental in patenting what was
considered to be a basic technology. Similarly, growing tension emerged between publishing research results
versus patenting them. Whilst the norms of the scientific community and the search for professional recognition
had long stressed rapid publication, patent laws prohibited the granting of a patent to an already published
discovery. In the second place the law surrounding the possibility of patenting life-formats and procedures
relating to the modification of life forms was not defined. This issue involved a variety of problems, but
essentially boiled down, first, to whether living entities could be patented at all; and, second, to the scope of the
claims that could be granted to such a patent (Merges and Nelson, 1994). The Bayh–Dole act of 1980 greatly
facilitated university patenting and licensing, but the emergence of the industry–university connection depended
very greatly on the revolutionary developments in micro–electronics and biotechnology in the second half of the
20th century.
30J.O. - L 213 of 30.7.98
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was one in which national legislation did not include, in general, legal principles that
prohibit the granting of patents on living matter, but at the same time it did not offer
definitions and general principles, much less specific guidelines, to manage the most
controversial problems. At the same time, biotechnological inventions were de facto
patented in most countries.
According to an OECD study on patenting practice in 22 member countries31, all
reporting countries allowed patentability without exceptions for a large variety of
objects. National differences concern the patentability of plants per se, parts of plants
or vegetal varieties; and of animals per se, animal organs or animal varieties. All
countries excluded the patentability of human beings, human organs or derived
products of human origin, including  cell lines, genes and sequences of nucleic acids
or amino-acids. However, an isolated element of the human body, or obtained
through a technical process, including the sequence or partial sequence of a gene,
might be patentable, even though its structure may be identical to the naturally
occurring one.
It is clear that national legislation does not include, in general, any legal principles
that prohibit the patentability of biotechnological inventions. At the same time,
however, the implementation of patentability is subject to a number of specific norms
that require explicit treatment by national legislators.
Directive 98/44 is based on the principle that biotechnological inventions can be
patented but there may be specific exclusions depending on the nature of the
invention. These exclusions clearly address the ethical concern expressed in the
European Parliament and by the public opinion for the possibility of granting patents
on processes that may modify human genetic identity or utilise human genetic
materials in the organised form of embryos. However, the Directive is clear that an
invention cannot be excluded for the  sole reason that it concerns living matter.
A separate and relevant issue is the protection to intellectual property rights in
academic research. On the one side, it is argued that property rights would favour the
creation of markets for technology and hence a faster and more ordered diffusion and
                                                
31 These include Germany, Australia, Austria, Belgium, Canada, Korea, Denmark, Spain, United States, Finland,
France, Hungary, Italy, Japon, Norway, New Zealand, Netherlands, Czech Republic, United Kingdom, Sweden,
Switzerland, Turkey.
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use of knowledge. On the other side, some authors emphasise that strong protection
for intellectual property in academic research might ultimately hinder the search for
diversity which is intrinsic to the scientific activity. Scientists might be motivated
more by the need to reach a patentable result than by intrinsic interest of discovery.
In sum, a world of private science might be a world of poorer science. Clearly, these
arguments require closer scrutiny.
The concession of very broad claims on patents might also have a detrimental effect
on the rate of technical change, because they might preclude the exploration of
alternative applications of the patented invention. To the extent that such techniques
and knowledge are critical for further research that proceeds cumulatively on the
basis of the original invention, the attribution of broad property rights might hamper
further developments.
In general, the rationale of the establishment of strong IPRs as a means for the
development of markets for technology rests critically on the assumption of
competition among inventors. Thus, excessive concentration of patents might
constitute a legitimate source of concern, calling for a systematic connection between
IPR policy and antritrust.
Another line of criticism refers to the problem of sequential patents and blocking
patents. In biotechnology, many developments require the utilization of several
patents, which  may be owned by different players. Particularly with gene sequences,
industrial utilization may require the licensing of several patents in sequence. In
other words, a market for technologies should be put in place, where rights over
several pieces of knowledge are contracted for. If this is the case, then the owner of
the first patent in a row might behave opportunistically. The argument is in line with
the well known ‘tragedy of anti-commons’ raised by Heller and Eisenberg (1998):
while in the commons the lack of proprietary rights leads to over-utilization and
depletion of common goods, in biotechnology the risk may be that too many  rights,
creating a barrier to use of otherwise public knowledge, lead to under-utilisation.
High transaction costs are expected, with an upsurge of litigation and legal costs. The
effect can clearly be more negative in the case of cumulative technological change
and, moreover, for publicly-funded academic research. However, there several
remedies can be designed for this problem, such as cross-licensing, patent pools,
mergers or side payments (see also Shapiro, 2001).
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In synthesis, the debate about IPRs in biotechnology is still highly controversial and
problematic. The emergence of a regime where property rights can be precisely
defined and appropriated has been favourable to the development of the
biotechnology industry in the USA, especially as an incentive for the creation of
DBFs. At the same time, however, there is growing concern that the current US
system might not be sustainable in the long run. In Europe, the IPR situation is less
extreme and there is opposition to the Directive as well as problems of harmonisation
across national legislation. The issues raised clearly go much beyond biotechnology
and will continue to be controversial over the next decade(s). Within this
environment, the key concerns raised at the frontier of science and technology can
only be resolved through informed discussion, careful economic analysis, sound
policy debate, and finally and most importantly, democratic consensus.
VI. 5  Biotechnology Policies in Europe
It was suggested earlier that the slow pace of development of biotechnology in
Europe has been due to lack of the basic preconditions for innovative activities in
this field. These concern the scientific and industrial base, the organisational
structures linking science to industry, venture capital and intellectual property rights.
However, in recent years European biotechnology appears to have found new
dynamism. One possible reason for this might be that policies have begun to exert
some impact. Many European countries began to initiate policies supporting
biotechnology in the 1980s. These included measures to introduce some typical US
institutional features that have been crucial to the development of new biotechnology
start–ups (such as fostering venture capital, developing financial markets tailored for
new high risk companies, promoting the commercialisation of academic research and
the mobility between academia and commercial activities) but primarily aimed at
strengthening technology transfer and new firms formation. Efforts were also
directed towards supporting basic research in universities and national research
laboratories and, in some countries, firms (France). Furthermore, in the UK and
France the government has been instrumental in the foundation of some of the oldest
European biotechnology firms, namely Celltech in Britain and Transgene in France.
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The forms and rationale of public intervention have been quite different across
countries and regions. The experiences discussed below reflect such different
patterns.
The experience of the United Kingdom has been well documented by several studies,
like the Diebold Institute Entrepreneurship and Public Policy Project (moreover, see
DTI, 1999, 2001). Consequently, it is not covered in a specific section in this Report.
France
Starting in early 1980s, with the “mobilisation (later “expansion”) program”, public
effort has been directed in France to stimulate both private and public research in
biotechnology (see Lemariè, Mangematin, Torre, 2001). The majority of basic
research was actually conducted by public structures such as the Centre National de
la Recherche Scientifique (CNSR) and the Institute National de la Recherche
Medicale (INSERM). These institutes have also transferred funds to private
institutions like the Institute Pasteur. Several initiatives  were then  taken: beyond
supporting start-ups by venture capital and stimulating the creation of science and
technology transfer centres within the major universities and research institutes,
public funding was used to revitalise large established groups operating in the life
sciences. In the 1990s, with the launch of the BioAvenir program, the latter form of
intervention became more pronounced, as suggested by the joint support to Rhône
Poulenc and several public research centers, aimed at creating public–private
partnerships.
The improvement of some indicators of biotechnology activity in France, and then
the creation of a more solid scientific and technological base, became more evident
during the implementation of this “latent” national champion policy, in which a large
part of the public research system was made available to one private group. This
approach has been frequently blamed  for the slowdown in the birth of new firms in
the early nineties. However, this period was one of scarce interest of investors
towards biotechnology in general. In recent years, a renewal of interest towards start-
ups has characterised the French policy, with new initiatives aimed at promoting
knowledge transfer, mobility of scientists, and more generally, at increasing co-
ordination between different agents and at improving the control of funded projects.
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Moreover, the opening of the “Nouveau Marché” is a relevant channel to collect
financial resources.
Germany
Publicly funded research has been the primary source of biotechnology knowledge
also in Germany. The “Applied Biology and Biotechnology Program”, launched in
1986 by the Federal Ministry of Research and Technology, was intended to stimulate
biotechnology research in universities (by the creation, for example, of “Gene
Centers” at universities of Munich, Cologne, Heidelberg and Berlin) and knowledge
transfer to firms. Established chemical and pharmaceutical corporations were, in this
phase, the main subjects of such interventions.
Characteristics of recent public policies in Germany, such as support for an
environment encouraging new start–ups, and the “regional” focus in the development
of some high–tech industries, have also been evident especially in the US but also
elswhere in Europe. Local labour markets, specialised inputs and knowledge
spillovers are suggested to be the main factors contributing to such phenomena. The
Ministry of Research launched the BioRegio program in 1996 to create a competition
between 18 German regions, each of which expected to define research projects
based on biotechnology networks. Three of them (München, Rheinland and Rhein-
Neckar) “won” the competition and received extrafunding, and one, Jena, received a
special vote by the jury. This type of intervention is seen as one of the crucial factors
contributing to growth in the number of new biotechnology firms, after a decade
during which Germany had been losing its leading European position in life sciences.
However, such intervention has worked differently in different regions. In most of
them, firm and job creation has been limited, both in terms of number and size of
new firms, and then of new jobs. A review of the leading regions shows that the new
start–ups have been able to rely on a pre–existing, and quite diffused, knowledge
base, as represented by universities, research institutes, and even the chemical and
pharmaceutical industry. The case of the Rhine-Neckar is characteristic. The
majority of life science firms are located in the Heidelberg Technology Park (that is,
very close to University clinics and the German Cancer Research Centre), and,
furthermore, chemical and pharmaceutical companies have long been present in the
area. One can only speculate how the future will unfold once public support is over.
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Clearly, it is difficult to evaluate the effectiveness of different policy approaches and
arrive at one that might be preferable to others32. What emerges clearly, however, is
that forward-oriented policies can have an impact, but that the presence of other
factors – principally an established and developed knowledge and competence base –
are necessary to attain a “critical mass” for the growth of the sector. Even if policies
have played an important role in the recent dynamism of European biotechnology, it
is not easy to isolate the contribution of any particular intervention. As already noted,
the simultaneous presence of various factors appears to have played a determinant
role. In many countries, indeed, policies have often been criticised for the lack of co–
ordination between different measures and also the lack of a “strategic” vision.
In general, it is true that several member states have had policies to promote
biotechnology in place for several years. Although there has been some success,
notably in the promotion of biotechnology start-ups, the growth of DBFs in Europe
appears to be hindered. To a considerable extent, this may be due to regulatory,
entrepreneurial, fiscal and financial factors. However, in addition to these factors the
supply of cutting-edge scientific research may be inadequate. If so, this problem
could be addressed not only through higher levels of research funding but also
through higher degrees of pluralism in funding sources, lower dependence on closed
national systems, and higher integration of research with teaching, clinical research
and medical practice. One of the most effective means of achieving this would be
through the establishment of a European Research Area, starting from the
constitution of a single market for human capital in academic and non industrial
research.
                                                
32 Another interesting case is Denmark, where the development of biotechnology firms is in different ways
linked, according to many observers, to their relationship with large and established companies like Novo
Nordisk and Heineken. On the other hand, creating a favorable framework for foreign investment by providing
fiscal incentives has been central to Ireland’s biotechnology policy. The birth of new firms is mainly concentrated
in areas such as Dublin where, again, a solid knowledge base and a scientific community were already present.
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VI. 6 Other Institutional Factors: Public Perceptions and Overall Regulatory
Stance
Public perceptions and attitudes can affect the economic and regulatory conditions
under which an industry operates. Their impact can be felt through supply channels
(attraction towards young graduates and scientists, perceived social utility of related
research, perceived risk factors with respect to financial conditions), the economics
of the production or on the demand for the products and techniques that this industry
puts on the market.
Regulation tends to be specific to the field of application and the technology.
Generally, there cannot be any unequivocal judgement over its role as its short-term
effects may differ from its longer term ones. However, there is little doubt that the
regulatory framework can have a major impact on the competitiveness of
biotechnology in Europe.
Available research (Gaskell et al., 2000) seems to suggest that the European public
discriminate quite clearly among the fields of application of biotechnology.
Europeans are neutral about agricultural biotechnology and opposed to both
genetically modified food and the cloning of animals. By contrast, perceptions of
medical and environmental biotechnology are very positive.
In the EU, no new genetically modified organisms (GMOs) have been authorised to
be placed on the market for the past 3 years (since October 1998). Though the EU
has one of the strictest pre-market risk assessment systems in the form of Directive
90/220/EEC, revised this year (see Directive 2001/18/EC), Member States have
refused to authorise GMOs. As a consequence, genetically modified food products
have not been authorised under the sector-based legislation and the entry of new
genetically modified plant varieties onto the common catalogues was not possible,
despite positive assessments from the EU's scientific bodies.
The above situation and the uncertainty as to when authorisation of GMOs and
derived products may restart, has led the biotechnology industry to focus most of its
investments – especially concerning R&D and the basis for new start-ups and SMEs,
– in non-plant related areas, where mechanisms for product approval are in place and
functioning.
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This situation is in stark contrast with the one in the US, where markets for all areas
of biotechnology are in place.
VI.7. Adoption of Biotechnology Among Large European Firms
An important aspect of the development of European biotechnology is the
considerable lag, compared to American (and to some extent to British) companies,
in the adoption of new techniques, notably molecular biology, by many large
established companies. The relevance of this factor is crucial. During the Seventies
and the Eighties, given the low rate of creation of new firms, development of
biotechnology in Europe rested on the activities of large companies. Moreover, in the
absence of  vibrant research activity by large firms, prospective start-ups lacked an
essential source of survival and growth through the establishment of collaborative
agreements. As claimed previously, in the absence of such competencies, large
companies have turned to the American scientific and technological base to tap and
absorb the new requisite competencies during their catching-up process. Thus, in
Europe a vicious circle between the relative backwardness of large firms and low rate
of formation of new start-ups has been created.
The rate of adoption of biotechnology by established companies varied widely across
the world and across firms. Within Europe some large British and Swiss firms were
able to adopt the technology rather quickly. Other firms, with smaller research
functions, more local in scope or more orientated towards the exploitation of
established research, found the transition more difficult. Thus, almost all of the
established French, Italian, German and Japanese companies appear to have been
slow to adopt the new technologies. To be sure, some German companies (e.g.
Hoechst) were among the first to establish connections with the American research
base in biotechnology (as early as 1982 Hoechst signed a multi-million, ten-year
agreement with Massachusetts General Hospital). Nevertheless, the actual absorption
of the new technologies progresses on average more slowly in Europe as compared
to the USA. What factors have possibly contributed to this?
• The relative strength of the local science base again appears to be  relevant.
For example, Swiss firms have established strong connections with the US
scientific system, suggesting that geographic proximity as such has played a
much less important role in the diffusion of molecular biology.
85
• Second, it is possible that size and structure of the various national
pharmaceutical industries determines diffusion. The existence of a strong
national pharmaceutical industry, with some large internationalised
companies, may have been a fundamental factor in the rapid adoption of
biotechnology. In many European countries, the industry was highly
fragmented into small companies engaged essentially in the marketing of
licensed products and the development of minor products for the domestic
markets. However, while size or global reach may have been a necessary
condition, the delay of the largest German firms in adopting these techniques
suggests that it was not sufficient. The largest German firms were
undoubtedly among the most internationalised and largest companies in the
world.
• Another important factor may be the degree of diversification. Most
European firms have been large chemical firms, largely diversified into
different technologies and markets, ranging from chemicals and
pharmaceuticals to agricultural applications. US firms have been more
specialised in narrowly defined areas. In other words, even if chemistry was
the fundamental technological base for all firms, the European corporations
have been essentially defined by their chemical culture, whereas US firms
have been focused on more specific products and markets and, as a
consequence, perhaps, more ready to explore new and alternative research.
Moreover, in the early stage of development, biotechnology was often
perceived as an opportunity for synergies. Over time, however,
pharmaceutical, agro-food and chemical applications tended progressively to
diverge and to progress along distinct paths.
• An additional factor is the stringency of the regulatory environment. There is
now widespread recognition that the introduction of the 1962 Kefauver -
Harris Amendments had a significant impact in inducing a deep
transformation of the US pharmaceutical industry. Similarly, it has been
suggested that the European country whose leading firms did move more
rapidly to adopt the new techniques - Britain – also appears to have actively
encouraged a "harsher" competitive environment. This induced British firms
to pursue strategies aimed less at fragmentation of innovative efforts into
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numerous minor products than to the concentration on few important
products that could be diffused widely into the global market. By the 1970s,
the ensuing transformations of British firms had led to their increasing
expansion in world markets.
The diffusion of the new technologies has varied also across firms. Most of the firms
that rapidly adopted the new techniques have been large multinational or global
companies, with a strong research presence in the US and in international markets.
These firms had developed early a "taste" for science and were able to integrate the
new knowledge within the firms. This, in turn, was accomplished through
organisational changes directed towards building and sustaining close links with the
public research community through successful adoption academic-like forms of
organisation of research. Other institutional factors have also been necessary, albeit
not sufficient.
• First, it is possible that the Anglo-Saxon forms of corporate governance made
it easier for firms to “hire and fire” personnel or cut non-performing assets;
European companies seem to have hesitated giving long–term employment to
biologists before biology was proven to be successful over the long run.
• Second, it is possible that the American advantage in the use of
biotechnology within large corporations, as well as in new biotechnology
companies, relates to the proximity and availability of first rate scientific
research in universities and in the closer integration between industry and the
academic community. One might also speculate that this has been the result
of the strong scientific base of the American medical culture and of the
adoption of strict scientific procedures in clinical trials. Through this
mechanism, American companies might have to develop earlier and stronger
relationships with the biomedical community and with molecular biologists in
particular.
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VII. Industrial Competitiveness in Biotechnology. An Interpretative Framework
The commercial development of European biotechnology is still lagging significantly
behind the US. Despite encouraging signals of dynamism – especially in the small
Northern European countries – and a wave of entry of new DBFs – especially in
Germany – innovative activities remain far below the American levels. European
companies rely partially on American research while, more worryingly, US firms do
not seem to consider European research equally attractive. The new European DBFs,
furthermore, are much smaller than their American counterparts, much less active in
the global network of collaborative relations and in the markets for technology and
are mainly present in platform technologies.
To some extent, the European performance deficit in biotechnology is the result of its
late entry. Even in such a strongly science–based industry, innovative activities are
characterised by various forms of increasing returns and early entrants acquire long-
lasting leadership. This is a crucial point since it implies that catchingup is inherently
difficult. Yet, catchingup is possible, but it requires determined efforts to generate
the appropriate competencies, market signals and incentives.
Europe has had policies promoting biotechnology in place for several years and some
important results have already been achieved. It is possible that recent developments
suggest that the policies might have eventually begun to produce effects. Thus, it
could be that European biotechnology might takeoff suddenly and sooner than
expected.
However, the results of this chapter suggest that late entry is only part of the problem
and that the take–off of European biotechnology is still hindered by a variety of
structural factors. This leads to some general implications.
A systemic approach seems necessary
First, it is important to recognise that the lagging behind of European biotechnology
has also systemic causes, rather than being simply the result of specific market or
institutional failures. Successful innovative and commercial activities in this industry
depend on a delicate blend of competencies and incentives and require the
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integration and co-ordination of several differentiated agents, capabilities and
functions. Focusing on some specific aspects of the puzzle is not likely to yield the
desired outcomes but a co–ordinated strategy appears to be necessary.
Biotechnology involves the exploration of an enormous, imprecisely defined and
rapidly changing space of unknown opportunities. This requires both decentralisation
of efforts and a variety of approaches as well as an ability to integrate and co-
ordinate them. Clearly, this is a challenge where no unique optimal solution may
exist but in fact alternative strategies may be appropriate. For example, in the de-
codification of the human genome the Human Genome Project was achieved by
extreme decentralisation of tasks and approaches among a large number of
institutions while Celera Genomics approached it through strong centralisation of
resources and efforts. Both approaches have been partially successful and each
benefited from the existence of the other.
US leadership in biotechnology derives from a unique blend of capabilities and
institutional arrangements. These include a strong scientific, technological and
industrial base; mechanisms that favour communication and transfer of knowledge
between academia and industry; a financial system that promotes the starting up of
new, risky ventures; strong intellectual property protection; and a favourable climate
in terms of public perception and regulation that does not restrict genetic
experimentation. European biotechnology  should not blindly follow the US model.
Some aspects of the development of biotechnology in the US cause concern, such the
government’s reluctance to labelling genetically modified food. Europe has different
institutional settings, histories, traditions and competencies. On them, it might be
possible to develop a different, but equally successful road to competitiveness. Yet,
some basic lessons can be learned from the US case and serve as a source of
inspiration for European policy.
Strengthening basic scientific research and building a European research system
Second, it is clear that the availability of leading–edge scientific capabilities is one of
the fundamental preconditions for successful development of biotechnology. Without
a strong and diversified scientific research base, no technological take–off is
possible. Nor can the European industry simply tap  American scientific knowledge.
At the very least, acquiring knowledge implies the ability to produce knowledge.
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Access to the scientific community requires direct and active participation in the
networks of scientists. The dynamics (and the economics and sociology) of scientific
research is characterized by strong path–dependence and first–mover advantages.
Europe is lagging behind in this respect too. While centres of excellence exist,
Europe does not attract comparable levels of foreign resources, and European
biotechnology in the large companies relies significantly on American research.
Increased funding is certainly necessary, but it is only a part of the solution. An
important finding is that the European research system is weak in terms of
organisational diversity, it is specialised in rather narrow areas and is insufficiently
interconnected across different research areas, types of organisations and stages of
the research process. Thus, higher degrees of pluralism in funding sources, lower
dependence on closed national systems, and higher integration of research with
teaching, clinical research, and medical practice,   should become priorities of a
European research policy in this area, allowing more efficient exploitation of
available resources.
Finally, the European research system appears to be still too rigid, bureaucratic and
segregated. While important advances have been achieved in recent years, further
progress needs to be made in this respect.
Integration of research and industry
The European research system may still be insufficiently integrated with industrial
research. This is most likely a reflection of several factors, possibly that that
European industry does not fully exploit the potential offered by European science,
as well as institutional and organizational obstacles, which could be more directly
relevant here, such as low mobility of researchers and bureaucratic obstacles to
collaboration.
Policies in this area have focused on introducing incentives for academic researchers
to become involved in industrial research and building bridges between university
and industry as well as developing financial and infrastructure facilities like venture
capital, science parks, etc. In practice, these measures, important as they are, appear
to reflect an understanding of the innovation process as based on the transfer of
knowledge. However, because innovation is primarily an interactive process, more
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emphasis is necessary instead on how to integrate more directly different agents and
fragments of knowledge. To a considerable extent these difficulties derive from some
long–standing characteristics of the European academic systems, particularly the
integration of research and teaching and the structure of career paths in universities.
In fact, universities often lack the necessary organisational capabilities to sustain
intense interchange with industry. Again, considerable progress has been achieved in
this area in recent years, but science and industry continue to encounter difficulties in
their interactions. Thus, measures are necessary to favour the development of more
direct linkages between universities and industry, through the integration of research
and teaching and the development of markets for technology. These observations
apply both to the creation of university spin–offs and to the relationships between
universities and large corporations.
Sustaining the creation and development of dedicated biotechnology firms
The creation and development of a strong DBFs sector is a crucial priority. DBFs
constitute an important organizational device allowing the exploration of the new
opportunities. In Europe, this sector remains underdeveloped and  is concentrated in
few areas. Moreover, the European DBFs are hardly comparable with the American
biotechnology firms. Many are far too small, possibly because they are too
specialized in specific niches.
Once again, interventions aiming at promoting the birth of DBFs have been at the
center of European biotechnology policies for more than a decade. Still, the emphasis
is on strengthening of industry–university relations, the creation of the
“entrepreneurial university”, the development of venture capital and, to a lesser
extent, on intellectual property rights. Although these are important, the problem of
an inadequate supply of cutting–edge scientific research may not have been
sufficiently addressed. Moreover, venture capital may not necessarily be always a
solution considering that it might make the growth of DBFs hostage to stock market
fluctuations. While venture capital remains an essential instrument for supporting the
process of formation and early growth of the new firms, it ought to be understood as
one instrument within a wider array of sources of funding (including public research
funding) and managerial capabilities.
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Finally, it is important to recognize that DBFs exist in a relationship of strong
complementarity with the large corporations. The latter are fundamental sources of
demand for products and services of DBFs and provide crucial integration
capabilities for transforming different fragments of knowledge into products. Large
firms constitute reservoirs of technological and managerial competence. In general,
given the relationships between the creation and development of DBFs and the
research/absorptive capabilities of the large companies, policies for biotechnology
should be much more strongly linked to interventions aiming at raising the
competitiveness of “downstream” industries, mainly pharmaceutical (see also
Gambardella, Orsenigo, Pammolli, 2001).
Intellectual property rights
Intellectual property rights constitute one of the most delicate and important issues
for biotechnology. While problems of clarification and harmonization of the
legislation on these matters remain, the emerging European approach is on the whole
balanced and flexible enough to accommodate diverging requirements. The creation
of the Community Patent and the implementation of the Biotechnology Patent
Directive will provide a useful addition in this area, by making  EU-wide protection
easier.
It is useful to recall that rigorous regulation is not always  an impediment to scientific
and technological progress. On the contrary, it can be beneficial, both by providing
reassurance to society and by forcing industry to adopt higher quality standards
which, if combined with more streamlined administrative procedures, can lead it to
become more competitive and efficient. In this respect, the example of the regulatory
reforms concerning product approval in the pharmaceutical industry might be
instructive (see Thomas, 1994; Gambardella, Orsenigo, Pammolli, 2001). However,
unnecessarily onerous regulation can severely undermine competitiveness by placing
unnecessary constraints on innovation that may encourage individuals and companies
to relocate to other markets.
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